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I. Abstract 
 
BACKGROUND: In this study we have examined human vascular endothelial cells as targets 
for antigen-specific cytotoxic T lymphocytes (CTL). Vascular endothelial cells (EC) act as the 
major interface between blood and tissues and are crucial for the maintenance of vascular 
integrity. It has been shown previously that EC are poor targets for immunodominant antigen-
specific CTL. This feature was due to the impaired capacity of EC to present the cognate 
antigenic peptides to CTL. These findings fueled the hypothesis that EC present a 
substantially different repertoire of MHC class I ligands compared with syngeneic leukocyte 
derived cells and that they might be protected from CTL-mediated lysis by this mechanism. It 
was the object of this thesis to confirm or rule out this hypothesis.  
METHODS: Our study consisted of three parts. First, the peptide repertoire from endothelial 
cells was compared with syngeneic leukocyte-derived cells. Cell type-specific HLA-A*02 
restricted peptides were identified and characterized for several biochemical features like 
expression of source proteins, binding properties and decay that would explain preferential 
presentation by either one of the two cells. Next, a method for the induction of self-reactive 
CTL was established by using peptide-pulsed dendritic cells as antigen-presenting cells and 
the generation of CTL specific for the HLA-A*02 restricted endothelial self-peptides PTRF(56-
64) and CD59(106-114) was attempted. In the third part, we modified the endothelial peptide 
repertoire and interfered with the peptide presentation pathway to test the hypothesis that 
abundant endothelial peptides indeed compete with immunodominant antigens for 
presentation on the surface of EC. The surface antigenic profile was altered by two 
approaches: a) by transfection of influenza virus A matrix protein 1 gene to make EC 
recognizable for Flu(58-66)-specific CTL and b) by siRNA knockdown of the abundant EC-
specific peptides.  
RESULTS: We show for the first time that EC present a quantitatively different peptide 
repertoire with abundance of certain peptides, compared with leukocytes. The abundance of 
endothelial peptides is mainly caused by the preferential expression of the source proteins. 
This feature is immunologically interesting since it contributes twofold protection of EC from 
CTL-mediated lysis: a) by an extraordinary strong tolerance that exists against EC peptides 
and b) by competing with immunodominant peptides for the MHC class I binding site. Under 
conditions that were sufficient to generate CTL specific for certain immunodominant low 
abundant self-peptides induction of CTL against PTRF(56-64) and CD59(106-114) failed. 
Improvement of culture conditions by stabilization of the pMHC I complex or interference with 
inhibitory pathways affected again only the induction of CTL against low abundant self-
peptides but not against EC-specific peptides indicating that these peptides are particularly 
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tolerogenic. After modification of the endothelial peptide repertoire and knockdown of 
abundant EC peptides, EC became better targets for immunodominant CTL by increased 
presentation of endogenously processed peptides indicating that the selective presentation 
of PTRF(56-64) and CD59(106-114) can protect EC by hiding them from CTL-mediated lysis. 
CONCLUSION: Our in vitro findings are in accordance with the view that EC are protected 
from CTL-mediated lysis by presentation of a quantitatively different peptide repertoire. This 
protection results from peptides that compete with immunodominant peptides for the MHC 
class I binding site and, in addition, evoke extraordinary strong tolerance. 
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1. Introduction 
 
1.1 Autoimmune diseases - with particular emphasis on CD8+ T 
cells 
 
Self-reactive lymphocytes always exist in the natural immune repertoire but are not often 
activated. In autoimmune disease, however, the loss of self-tolerance and expansion of 
those cells after activation by specific autoantigens lead to tissue injury. From a clinical 
perspective it is useful to distinguish between the following two major patterns of 
autoimmune disease: the diseases in which the expression of autoimmunity is restricted to 
specific organs of the body (organ-specific autoimmune disease); and those in which many 
tissues of the body are affected (systemic autoimmune disease) (Table 1). Systemic 
autoimmune diseases affect multiple organs and have a tendency to become chronic, 
because the autoantigens can normally never be eliminated from the body. Organ-specific 
autoimmune diseases include type 1 diabetes mellitus, multiple sclerosis (MS), myasthenia 
gravis, Grave’s disease and Hashimoto’s thyroiditis. In each case, autoantigens from one or 
a few organs only are targeted, and disease is therefore limited to those particular organs: 
insulin-producing β cells of the pancreas (diabetes), the myelin sheathing axons in the 
central nervous system (MS), and the thyroid-stimulating hormone receptor (Grave’s 
disease). In contrast, systemic diseases like systemic lupus erythematosus (SLE) or 
scleroderma cause inflammation in multiple tissues because their autoantigens, which 
include chromatin and ribonucleoproteins, are found in every cell of the body. An overview of 
organ-specific and systemic autoimmune disease is shown in Table 1. 
Some autoimmune diseases seem to be dominated by the pathogenic effects of a particular 
immune effector pathway, either autoantibodies or activated autoreactive T cells. However, 
both of these pathways often contribute to the overall pathogenesis of autoimmune disease. 
The damage by autoantibodies is mediated through the complement and Fc receptor 
systems. Systemic lupus erythematosus (SLE) is an immune-mediated, multi-system disease 
characterized by pathogenic autoantibodies against nuclear antigens [1]. T cells contribute to 
autoimmune disease in two ways: by helping B cells to make autoantibodies, in an 
analogous manner to a normal T-dependent immune response, and by direct effector 
functions of T cells as they infiltrate and destroy target tissues such as skin, renal interstitium 
and vessels as would virus-infected cells.  
The importance of CD8+ T cells in the pathogenesis of organ-specific human autoimmune 
diseases has previously not been well recognized. There are several reasons for the neglect 
of the role of CD8+ T cells in autoimmunity. First, it is much more difficult to demonstrate the 
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existence of autoreactive T cells than it is to demonstrate the presence of autoantibodies. In 
animal models, the disease can be transferred by injecting the active component of the 
immune response from one animal into another to obtain the most convincing proof that the 
immune response is causal in autoimmunity. Autoreactive human T cells cannot be used to 
transfer disease to experimental animals because T cell recognition is MHC-restricted. 
Second, it is difficult to detect the antigen recognized by a T cell. The identification of 
autoantigens is particularly difficult in autoimmune diseases in which CD8+ T cells have a 
role, because autoantigens recognized by CD8+ T cells are not effectively presented by MHC 
class I molecules. Third, there is a lack of measures to detect autoreactive T cells as the 
relevant disease-associated populations act in the tissue lesion, and circulate only at very 
low precursor frequencies in the peripheral blood.  
Several experimental studies described the importance of autoreactive CD8+ effector T cells 
in experimental autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, 
autoimmune thyroiditis, and multiple sclerosis. Autoreactive CD8+ T cells can be responsible 
for the selective β cell destruction that is the hallmark of clinical type 1 diabetes. They are 
involved in the initiation of insulitis and in the destructive stage leading to insulin-dependent 
diabetes mellitus [2]. CD8+ T cells are dominant among islet-infiltrating lymphocytes and are 
required for efficient diabetes induction upon adoptive lymphocyte transfer in the model of 
spontaneously diabetic NOD mice. CTL are involved both in initiation of β cell-directed 
autoimmunity and in ultimate destruction of β cells preceding manifest disease. Multiple 
sclerosis (MS) is a chronic human disease caused by inflammatory cell-induced 
demyelination in the central nervous system. Infiltrating CD8+ T cells predominate over CD4+ 
T cells, especially in regions of active demyelination, and these CD8+ T cells appear to 
undergo local clonal expansion as assessed by analysis of TCR gene rearrangements at the 
single-cell level [3]. Autoreactive CD8+ T cells responsive to myelin-derived peptides have 
been reported in MS patients that have the potential to kill HLA class I-matched 
oligodendrocytes in vitro, independent of exogenous peptide. Experimental autoimmune 
encephalomyelitis (EAE) is an experimental model for MS, induced in susceptible animals by 
immunization with myelin antigens. Although autoreactive CD4+ T cells are implicated as 
major effectors of EAE, there is evidence pointing to a role for CD8+ T cells in disease 
progression and severity. For example, a myelin oligodendrocyte glycoprotein-derived 
peptide (MOG) has recently been shown to elicit encephalitogenic CD8+ T cells in vivo [4]. In 
addition, myelin basic protein (MBP) is processed and presented in vivo by the MHC class I 
pathway, and, in fact, responding CD8+ T cell clones induce a CNS immunopathology in mice 
that resembles some forms of MS, implicating CD8+ T cells as potential effectors of 
demyelination in MS [5]. All these findings, however, indicate that autoreactive CD8+ T cells 
can contribute substantially to tissue damage in both murine and human autoimmune 
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disorders. As such, these T cells now become an attractive target for therapeutic 
intervention. 
 
Table 1. Classification of autoimmune diseases. 
Disease Effectors Antigens Experimental model References 
Organ-specific autoimmune diseases 
Type 1 diabetes 
mellitus 
Autoreactive T cells 
(Autoantibodies) 
Insulin 
β-cell antigens 
NOD (non-obese 
diabetic) mouse 
[2, 6] 
Goodpasture’s 
Syndrome 
Autoantibodies Collagen Type IV Fcγ receptor IIB–
deficient mouse 
[7] 
Multiple sclerosis Autoreactive T cells 
T helper cells 
Autoantibodies? 
Myelin basic 
protein (MBP) 
Myelin 
oligodendrocyte 
glycoprotein 
(MOG) 
Murine experimental 
autoimmune 
encephalomyelitis (EAE) 
[3-5] 
Grave’s Disease Autoantibodies TSH receptor Thyrotropin receptor-
induced mouse  
[8] 
Hashimoto 
thyroiditis 
Autoantibodies 
Autoreactive T cells 
Thyroid 
peroxidase 
Murine experimental 
autoimmune thyroiditis 
(EAT)  
[9] 
Myasthenia 
gravis 
Autoantibodies Acetylcholine 
receptor 
Murine experimental 
autoimmune myasthenia 
gravis (EAMG) 
[10] 
Autoimmune 
hemolytic anemia 
Autoantibodies Rhesus antigens Murine induced 
autoimmune hemolytic 
anemia (AIHA) 
[11] 
Systemic autoimmune diseases 
Scleroderma Autoantibodies Centrosome 
proteins, 
ribonucleoprotein 
antigens 
Tight skin (TSK) mouse [12] 
Giant cell arteritis Antigen-specific T 
cells 
Macrophages (Giant 
cells) 
Viral antigens? GCA (Giant cell 
arteritis)-SCID model 
[13] 
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Table 1. Classification of autoimmune diseases (continued). 
Disease Effectors Antigens Experimental model References 
Polyarteritis 
nodosa 
Autoantibodies 
Antigen-specific T 
cells 
Antineutrophil 
cytoplasmic 
antibodies 
(ANCA) 
Antiendothelial 
cell antibodies 
(AECA) 
SCG/Kj mouse [14, 15] 
Systemic lupus 
erythematosus 
Autoantibodies 
Autoreactive T cells 
DNA, chromatin 
proteins, 
ribonucleoprotein 
antigens 
(NZBxNZW)F1,MRL/lpr 
mouse 
[16-18] 
Rheumatoid 
arthritis 
Autoreactive T cells 
Autoantibodies 
Antigens of joint 
synovium 
Murine collagen-
induced arthritis (CIA) in 
DBA/1 
[19] 
Sjögren’s 
Syndrome 
Autoantibodies 
Autoreactive T cells 
Ribonucleoprotein 
antigens 
MRL/MpJ-lpr/lpr mouse [20] 
 
 
 
1.2 Normal T cell activation, tolerance and autoimmunity 
 
Pro-T lymphocytes arise from stem cells in the bone marrow and migrate to the thymus for 
maturation. The thymus is the primary lymphoid organ involved in T cell generation. There, 
mature T cells are selected from a pool of immature CD4+CD8+ double positive thymocytes 
dependent on how their T cell receptors (TCR) interact with self-peptide–MHC (self-pMHC) 
ligands [21-25]. The TCR is the highly variable antigen receptor of CD8+ or CD4+ T cells that 
recognizes antigenic peptide bound to major histocompatibility complex (MHC) class I or II 
molecules, respectively, on target cells [26]. The degree of inflammation, precursor 
frequency, antigenic signal strength and duration determines the efficiency of pre-T cell 
differentiation [27-31]. Thymocytes expressing TCRs that fail to recognize any self-pMHC 
ligand presented by thymic dendritic cells die by 'neglect', while weak recognition of self-
pMHC complexes by the TCR results in the development of mature, single positive T cells 
(positive selection). Strong recognition of self-pMHC leads to thymocyte death or lineage 
deviation and removal of self-reactive cells from the T cell repertoire (negative selection) [32, 
33]. Therefore, the peripheral T cell repertoire is both self-pMHC restricted and self-tolerant. 
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However, central tolerance is incomplete, and autoreactive T cells can escape negative 
selection [34]. In addition, some self-antigens do not access the thymus [35] or are not 
expressed in the thymus at levels required for efficient negative selection, while others may 
be expressed later in life, after the T cell repertoire has formed. Therefore, central tolerance 
needs to be buttressed by peripheral mechanisms [36, 37]. 
After leaving the thymus, each mature naïve T cell possesses a unique TCR specific for one 
antigen and a single coreceptor, either CD4 or CD8 for forming the interaction with MHC 
class II or I, respectively. T cells are then homing to the secondary lymphoid organs like 
lymph nodes, spleen or mucosa-associated lymphoid tissue (MALT) to encounter an antigen-
presenting cell (APC) bearing the cognate antigen leading to activation and proliferation of 
the T cells into effector cells. For the activation of naïve CD8+ T cells into cytotoxic effector T 
cells several concomitant signals are required. The first signal results from the interaction of 
the TCR with the peptide-MHC class I complex as described above. This interaction is further 
stabilized by the CD8 co-receptor. A second signal is delivered through costimulatory ligands 
that are highly expressed on activated APC as CD80 and CD86 that bind to the CD28 
receptor. As a third signal for the induction of a CTL response, cytokines like IL-2 are critical 
to support T cell survival and differentiation [38, 39]. Generally, cytokines are not only 
produced by activated CD8+ T cells but particularly effectively by T helper cells or other 
leukocytes. 
Peripheral tolerance can be achieved by multiple means and can be classified into three 
main categories: ignorance, death by deletion and anergy (functional unresponsiveness). 
The most likely candidates for ignorance are low avidity self-antigens, which fail to initiate 
negative selection. For normal peripheral T cell activation a higher TCR/pMHC affinity is 
required than for what results in thymic deletion [40]. These antigens, therefore, might never 
induce peripheral immune activation, and the population of self-antigen specific naïve T cells 
could potentially remain untouched. Another possibility of achieving peripheral ignorance is 
when antigens are restricted to immune privileged sites, such as across the blood–brain 
barrier or across the fetal–maternal barrier [40]. However, this form of tolerance is not 
permanent, as there are situations where the antigen could be presented under the right 
costimulatory conditions lowering the activation threshold. This might result in fatal immune 
responses [41]. Both anergy and activation induced clonal deletion are effects of incomplete 
activation of T cells in the absence of costimulatory signals. Deletion of autoreactive T cells is 
the most permanent and irrevocable form of peripheral tolerance. The factors that influence 
the decision for one of the two cell fates are not completely understood. Antigenic 
persistence has been found to be an important variable in determination of either deletion or 
survival [42]. When relatively small numbers of T cells are confronted with an excess of 
antigen or the antigen is present in the system for a long time, the CTL disappear. This has 
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first been shown in the context of infection with non-cytopathic viruses [43] but was also 
found to be induced by retroviral superantigens, by the injection of peptides in varying doses 
without or with adjuvant or of cells expressing a defined foreign antigen [44]. The details are 
poorly understood, but cell death by interleukin-deprivation and other mechanisms 
associated with apoptosis seem to be involved [45, 46]. A third mechanism of peripheral 
tolerance in naïve CD8+ T cells is the induction of anergy. Anergy is a form of functional 
unresponsiveness, believed to occur when a T cell has been subjected to TCR/pMHC 
interaction in the absence of costimulation. On the basis of the in vitro anergy model systems 
it has been shown that the molecular mechanisms involved in anergy induction comprise 
interference in TCR signaling by downstream signaling molecules. Thus, excessive 
calcium/NFAT signaling results in transcriptional upregulation of negative regulatory proteins 
that inhibit correct TCR/CD28 signaling [47, 48]. An anergic T cell is rendered refractory to 
further stimulation, even in the presence of full costimulation [49]. The hallmarks of anergic 
cells are defects in proliferation and IL-2 production, but other effector functions show 
variable (or sometimes no) reduction [50]. Autoimmunity arises when these strategies fail 
and the lymphocytes are activated to mistakenly target ‘self’ (i.e. normal tissues).  
Cytotoxic T lymphocytes (CTL) are one of the antigen-specific receptor arms of the adaptive 
immune system [51]. They were originally discovered as mediators of solid organ transplant 
rejection and graft-versus-host disease (GVHD) as prototypes of T cell-mediated immune 
diseases resulting from pMHC mismatch, but are physiologically important for immune 
defense against non-cytopathic intracellular microorganisms (e.g. EBV or CMV) and tumors 
[52]. Tissue injury by effector CTL critically depends on the binding avidity of the TCR for an 
antigen and the amount of antigen presented by target cells [51, 53]. Effector CTL kill 
antigen-bearing cells within minutes to hours by at least three different effector pathways 
[54]. Upon recognizing their cognate antigen, CTL release perforin and granzyme from 
preformed granules. Perforin forms pores in the plasma membrane of the target cell and 
allows granzymes to enter and cause apoptotic cell death [55]. The membrane-bound 
executor molecule CD95L is upregulated on CTL after TCR activation and induces apoptosis 
after binding to Fas (CD95) on target cells. Activated CTL synthesize and release cytokines, 
such as tumor necrosis factor-α (TNF-α). Their effect on target cells depends on the cell type 
and cellular activation state ranging in effect from apoptosis to survival. Fully differentiated 
effector CTL are capable to kill antigen-presenting target cells in the absence of any 
costimulatory signals or co-receptors. 
The majority of reactive effector CTL that emerge after clonal expansion are short-lived and 
undergo apoptosis after their task is accomplished, i.e. the antigen-bearing target cells are 
eliminated. Only a small number of antigen-experienced cells survive for a long time as 
memory T cells. Upon re-encounter with their cognate antigen, memory T cells can very 
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efficiently respond by strong proliferation and undergo a rapid transition into effector CTL 
[56]. 
Studies of the triggers leading to activation of autoreactive T cells and further autoimmune 
disease revealed two important mechanisms. First, a previously described nonconventional 
mechanism of Ag presentation, “cross-priming” or “cross-presentation,” has been shown to 
be involved in the maintenance and/or amplification of autoreactive T cells [57]. Professional 
antigen-presenting cells are able to cross-present self-antigens to T cells and thereby 
activate them. Kurts et al. showed that adoptively transferred or thymically derived OT-I cells 
activated by cross-presentation are deleted from the peripheral pool of recirculating 
lymphocytes [57]. These findings were at odds with numerous reports showing that cross-
presentation of exogenous antigen can prime class I-restricted CTL responses [40, 58]. 
However, the efficacy of cross-presentation leading to deletion may be affected by the 
antigen level in the target tissue, induction of apoptosis in self-antigen-expressing cells, 
presence of autoreactive CD4+ T cells and immune complex-forming autoantibodies, and 
high T cell precursor frequency [59, 60]. A second dominant paradigm for explaining the 
apparent links between certain autoimmune diseases and infection is the molecular mimicry 
theory [61-63]. Triggering of autoaggressive T lymphocytes by non-self antigens during 
infection and subsequent cross-reactive T cell recognition of a similar self-antigen, together 
with selective up-regulation of certain host proteins, virus-induced changes in the processing 
of host proteins, enhanced APC function, and proinflammatory environmental conditioning 
can all facilitate induction of autoimmunity or immunopathology by viral infections [64, 65]. 
For example, antimyelin autoimmune reactions in MS may be induced by viruses that share 
cross-reactive T and B cell epitopes with myelin Ags [66]. 
In addition to the mechanisms described, there are also cell-based protection mechanisms 
against autoimmune disease. Naturally occurring Foxp3+CD4+CD25+ T regulatory cells 
(Treg) are important for the establishment and maintenance of self-tolerance and the 
prevention of autoimmune and inflammatory manifestations [67, 68]. Treg exert a continuous 
control in the periphery of self-reactive T cells that have escaped central tolerance 
processes, as conditional ablation of Foxp3-expressing cells leads to overt autoimmune 
disorders in adult mice [68]. Treg can be used to promote antigen-specific tolerance for 
transplantation tolerance [69, 70], prevention of graft versus host disease [71, 72] and gene 
transfer applications [73-76]. While the ontogeny, phenotype and gene expression profile of 
Treg have been characterized in details, their mode of action and in particular the 
mechanisms by which they suppress CTL responses are still poorly understood. 
The last group of modulators of autoimmunity are negative or inhibitory costimulatory 
molecules that regulate T cell activation and play a role in peripheral tolerance. The 
realization that efficient T cell activation requires two signals led to the search for the 
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costimulatory signal and identification of the CD28-B7 pathway in the early 1990s [77, 78]. 
Members of the B7-CD28 family play important roles in regulating T cell activation and 
peripheral tolerance [79]. Soon after the discovery of the CD28-B7 positive costimulatory 
pathway, it became apparent that CTL-associated antigen 4 (CTLA-4), a second inducible 
receptor that is homologous to CD28 and binds with higher affinity to CD80 and CD86, could 
function as a negative regulator of T cell activation [80, 81]. CTLA-4 is also constitutively 
expressed on Tregs [82] and is important for their function [83, 84] and generation [85]. In 
addition, CTLA-4–mediated negative signaling is required for establishing peripheral 
tolerance [86-88]. Fife et al. showed that selective expression of a single-chain, membrane-
bound anti-CTLA-4 Ab on B cells leads to significant protection against disease in the NOD 
mouse by direct attenuation of autoreactive T cell activation [89]. Recently, novel CD28 
family members, including ICOS, programmed death-1 (PD-1), and B and T lymphocyte 
attenuator (BTLA), and new B7 family members, including ICOS ligand (ICOSL) (also known 
as B7-H), PD-1 ligand (PD-L1) (also known as B7-H1), and PD-L2 (B7-DC), having varied 
expression patterns among both lymphoid and nonlymphoid (parenchymal) tissues, have 
been described, providing further insight into the complexity of the functions of T cell 
costimulatory pathways [90, 91]. PD-1 and its ligands regulate both the induction and 
maintenance of peripheral CD8+ T cell tolerance [92] and indicate a previously unknown 
function for PD-L1 on non-hematopoietic cells in protecting tissues from autoimmune attack 
[93]. A further important role has been described for PD-1 in the restoring of exhausted T 
cells. Exhaustion of CD8+ T cell function was originally described during chronic LCMV 
infection as the persistence of virus-specific CD8+ T cells that lacked effector functions [94]. 
CD8+ T cell exhaustion appears to be a prominent feature not only of experimental chronic 
infections in mice but also during chronic infections in primates and humans for example in 
HIV, Hepatitis B and C [95-98]. Blockade of the PD-1/PD-L1 pathway reinvigorates the 
exhausted T cells, allowing them to expand and produce effector cytokines. 
In summary, an efficient CTL-mediated immune response is initiated if a naïve or memory 
CTL recognizes specific peptide-MHC class I complexes with enough avidity on an activated 
APC along with costimulatory signals. Under normal circumstances, central and peripheral 
tolerance mechanisms control the CD8+ T cell repertoire which is prepared to respond 
vigorously against pathogen-derived or alloantigens but not against self-antigens. 
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1.3 Interactions between endothelial cells and CTL 
 
Human vascular endothelial cells (EC) represent the major interface between blood and 
tissues. Forming the inner lining of blood vessels, they are crucial for the maintenance of 
vascular integrity, a prerequisite of organ homeostasis by preventing blood coagulation, 
regulating vasomotion and modulating permeability for molecules, particles and cells. EC are 
uniquely positioned between circulating lymphocytes in the blood and tissues. They are 
gatekeepers that regulate the trafficking of T lymphocytes from the bloodstream to sites of 
infection and inflammation and back to the lymphoid organs. EC express MHC class I 
molecules [99] and can therefore easily become targets of CD8+ CTL.  
Following transplantation of vascularized organs, EC are the first graft cells encountered by 
alloreactive host lymphocytes and therefore primary targets of alloreactive CTL [100, 101]. 
Different roles have been described for EC that interact with antigen-specific CTL [102]. It 
has been shown by several groups that EC are able to activate memory CD8+ T cells to 
differentiate into allospecific MHC class I-restricted CTL in vitro [103-105] and in vivo [106, 
107]. Moreover, EC exhibit important functions of professional APC, including expression of 
MHC class II and costimulatory molecules [108] and cross-presentation of minor 
histocompatibility antigens [109, 110]. The notion that EC may under particular 
circumstances act as APC has been supported by the finding that nonhematopoietic cells 
within the vascularized grafts – presumably EC – are able to initiate CTL responses that 
mediate allograft rejection [107]. 
However, the direct interaction of CD8+ T lymphocytes with allogenic endothelial cells results 
in unconventional effector CTL that are specific for EC but fail to kill leukocyte-derived target 
cells from the same donor [103]. Further, EC can be possible targets of CTL-mediated 
immune responses. When EC present cognate antigen that activates transmigrating effector 
CTL they should be targets and die rapidly from this interaction. However, the outcome of an 
interaction between effector CTL and EC can be manifold. Severe, immune mediated 
endothelial injury precipitates rapid organ dysfunction, such as seen in hyperacute solid 
organ transplant rejection [111, 112] caused by antibodies that non-specifically activate 
circulating T lymphocytes [113] or by certain cytokines, e.g. TNF-α [114]. However, CTL that 
are important mediators of acute graft versus host disease (GVHD) after allogeneic stem cell 
transplantation [115, 116] do not precipitate this type of rapid endothelial injury and EC are 
rather poor targets for peptide-specific CTL. Overall, endothelial injury is a rather uncommon 
event [106] as it occurs often only after long-during chronic stimulation, e.g. CTL-mediated 
injury of EC is found only late in the course of GVHD [117, 118]. Furthermore, T cells play an 
important role in the pathogenesis of common chronic inflammatory vasculopathies like 
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atherosclerosis [119] or different forms of large and medium vessel vasculitides [120] but it is 
unknown if EC are targets of autoreactive antigen-specific CTL in these diseases. 
To identify the underlying molecular mechanism of cell-selective tissue injury, Kummer et al. 
[121] chose the HLA-A*02-bound male-specific peptide SMCY(311-319) from the broad 
spectrum of possible MHC class I restricted alloantigens in order to simplify the complex 
interaction of CTL with EC. Again, EC were poor targets for peptide-specific CTL compared 
to other target cells. This resistance to CTL-mediated lysis was explained by the inability of 
EC to present equal amounts of immunodominant antigenic peptides compared to the other 
target cells. Neither a general resistance of EC to CTL-mediated target cell lysis nor lack of 
costimulation or low MHC class I expression did explain the fact that EC escaped CTL-
mediated lysis. The findings supported the accumulating evidence that EC present a 
substantially different repertoire of MHC class I ligands compared with syngeneic leukocyte 
derived cells and that they are protected from CTL-mediated lysis by this mechanism. 
 
 
 
1.4 MHC class I-restricted antigen presentation 
 
MHC class I molecules are essentially expressed on the surface of any nucleated 
mammalian cell and the copy number is estimated to be 50-100.000 per cell [122, 123]. The 
α-chain of the MHC class I molecule is highly polymorphic at all three MHC class I loci. The 
β-chain (β2-microglobulin) is non-polymorphic and not involved in peptide binding nor in 
direct contact with the TCR. EC express mostly HLA-A and B loci, but at a low baseline level. 
Upon activation with cytokines (TNF-α, IFN-γ), MHC class I molecules (and also various 
adhesion molecules) in EC can be rapidly upregulated [124]. IFN-γ and TNF-α act 
synergistically on vascular endothelial cells inducing a more than additional response of two 
signals [125]. Enhanced presentation of endogenous peptides and upregulation of adhesion 
and costimulatory molecules favor engagement of CTL [121]. 
MHC class I-restricted antigens are peptides of 8-9 amino acids length either derived from 
endogenous [126] or intracellular proteins that are degraded by the proteasome in the 
cytoplasma or within the ER [127] (Figure 1). Cytosolic peptides allocated to the MHC class I 
presentation pathway are transported via the transporter associated with antigen processing 
(TAP) [128] from the cytosol into the lumen of the endoplasmic reticulum (ER). TAP strongly 
affects the MHC class I ligand profile on cells [129]. Peptides are assembled with MHC class 
I molecules in a complex in the presence of chaperones [130]. Finally, the peptide-MHC 
class I (pMHC) complexes are transferred to the cell surface and there presented to other 
cells [131, 132]. The HLA-A*0201 molecule is carried by 40% of the caucasian individuals. 
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HLA-A*0201-restricted, immunodominant viral peptides are therefore extensively 
characterized [133, 134]. The efficiency of peptide presentation is influenced by numerous 
factors that act on three different levels: the processing of the antigen, the presentation of the 
peptide-MHC class I complex on the cell surface and the decay of the complex. The 
intracellular fate of source proteins for MHC class I ligands has been studied over the past 
years [131, 135]. The rate of source protein synthesis is one critical component that defines 
the amount of protein delivered to the proteasome for degradation [136, 137]. Due to the 
short half-life of peptides in the cytosol [138], the site of protein synthesis as well as TAP 
transport rates [139, 140] are also important components. The cellular protein degrading 
machinery consisting of the proteasome, cytosolic and ER proteases generates the antigenic 
peptides that can enter the ER [135, 138] and can thereby critically affect the MHC class I 
ligand repertoire [135]. The constitutive proteasome and the IFN-γ inducible 
immunoproteasome are shaping immunogenic peptides differently [141-143]. The 
immunoproteasome has been found to be important in particular for the generation of CD8+ T 
cell epitopes during viral infections and inflammation [144]. The presentation of the pMHC 
complex on the surface depends mainly from the stability of the complex. Poor affinity for the 
MHC molecule can abolish a peptide’s role as a surface antigen [145]. A further component 
influencing the quality of the presentation of the pMHC complex to CTL is its decay which is 
determined by the half-life of the complex [146, 147] but also by the internalization of MHC I 
molecules [148, 149]. 
 
 
Figure 1. MHC class I presentation pathway. 
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1.5 The MHC class I-restricted peptides used in this study 
 
In our study, we wanted to elucidate the special protection of EC in CTL-mediated lysis. 
Therefore, several MHC class I restricted peptides were used (Table 2). First, the endothelial 
cell-selective peptides PTRF(56-64) and CD59(106-114). PTRF(56-64) is derived from the protein 
polymerase I and transcript-release factor (PTRF). The sequence for PTRF is located on 
chromosome 17q21. It was initially discovered as a murine nuclear factor involved in RNA 
polymerase I transcription termination [150] and by this mechanism enhances transcription 
[151]. It has been further shown to suppress type I collagen promoter activity [152]. Recent 
reports described PTRF to be enriched in associated with caveolae in adipocytes in humans 
and rats as well as endothelial cells [153, 154]. CD59 located on chromosome 11p13 is a 
GPI-anchored complement inhibitor mainly expressed on erythrocytes [155] and leukocytes 
[156], but some expression is found in most tissues. Its major function is to inhibit the 
formation of the membrane attack complex by binding to C8/C9 [157]. Recent studies 
showed that CD59 is also expressed in human EC and protective against complement-
mediated lysis [158] and atherosclerosis [159]. One interesting feature is that the CD59(106-114) 
peptide is located in the proprotein (signal peptide) and not in the mature, GPI-anchored 
extracellular CD59. This suggests that the amount of CD59(106-114) presented on EC depends 
on the rate of synthesis and not on the rate of degradation.  
Further, several control antigens derived from foreign and self-proteins were used. As a first 
control peptide, Flu(58-66) was chosen, a peptide that is derived from influenza A virus matrix 
protein [133, 160]. As most adults have been exposed to influenza virus, a high precursor 
frequency of naïve or memory CTL in the PBMC of healthy HLA-A*02 positive donors can be 
expected. The second antigen, SMCY(311-319), is a Y-chromosome encoded, male-specific 
minor histocompatibility antigen in sex mismatched, HLA-identical hematopoietic stem cell 
transplantation [161, 162]. It is a low abundant self-peptide that can be used as an 
alloantigen when stimulating female responder PBMC and as an autoantigen for male 
donors. As a control for highly abundant self-peptides we used DDX5(168-176) (DEAD box 
polypeptide 5, p68), a conserved and ubiquitously expressed member of the DEAD box 
family of proteins with RNA helicase activity [163] which was used as a self-antigen for male 
PBMC donors. 
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Table 2. peptides used for experiments 
Flu(58-66) GILGFVFTL influenza-virus derived antigen foreign 
SMCY(311-319) FIDSYICQV alloantigen for females, 
autoantigen for males 
self, low abundance 
DDX5(168-176) YLLPAIVHI autoantigen self, high abundance 
PTRF(56-64) SLLDKIIGA autoantigen, endothelial self, high abundance 
CD59(106-114) SLSEKTVLL autoantigen, endothelial self, high abundance 
 
 
 
1.6 Aims of this study 
 
Several findings did support the hypothesis that EC present a substantially different 
repertoire of MHC class I ligands compared with syngeneic leukocyte derived cells and that 
they may be protected from CTL-mediated lysis by this mechanism. The major aim of this 
thesis project was to characterize the endothelial repertoire of MHC class I ligands, to 
investigate antigen-expressing EC as target cells for antigen-specific CTL in vitro, to assess 
the outcome of this interaction and to analyze immunogenicity of endothelial peptide-MHC 
class I complexes.  
 
In this project, the following aims were pursued:  
  
1. To identify and characterize the endothelium-specific peptide repertoire  
The peptide repertoire of endothelial cells and syngeneic leukocyte derived cells was 
compared. Therefore, MHC class I-restricted peptides were isolated from both cell lines 
and characterized by mass spectrometry.  
 
2. To elucidate which molecular mechanisms affect endothelial peptide presentation 
Several biochemical features of the identified peptides were characterized. Levels of 
protein expression and turnover, antigen processing by the proteasome and 
presentation and decay of the pMHC complex that are all critical steps of the MHC class 
I presentation pathway were analyzed whether they are involved in the selective 
expression of endothelial peptides. 
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3. To grow endothelial cell peptide-specific CTL from the blood of healthy donors 
First, a method for induction of self-reactive CTL was established. Peptide-pulsed 
dendritic cells were used as antigen-presenting cells to induce peptide-specific CTL. The 
induction of CTL specific for the HLA-A*02 restricted endothelial self-peptides PTRF(56-64) 
and CD59(106-114) was attempted under various culture conditions including stabilization of 
the pMHC complex and interference with inhibitory costimulatory molecules like PD-1. 
 
4. To modify the endothelial peptide repertoire with an attempt to break 
immunoprotection of these cells 
The surface antigenic profile was altered by two approaches: a) by transfection of 
influenza virus A matrix protein 1 gene to make EC recognizable for Flu(58-66)-specific 
CTL and b) by RNA interference to knockdown the abundant endothelium-specific 
peptides.  
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2. Material and Methods 
 
2.1 Culture media 
 
For culturing BLC complete RPMI 1640 medium, on the basis of RPMI 1640 (52400025) 
containing 10% FCS (10270106), 2 mM L-glutamine (25030024), 100 U/ml penicillin and 100 
µg/ml streptomycin (15140122), 5 mM nonessential amino acids (11140035), 5 mM sodium 
pyruvate (11360039) (all reagents from Invitrogen Life Technologies, Carlsbad, CA, USA) 
was generally used. RPMI 1640 washing medium is based on RPMI 1640 containing 2.5% 
FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin. As cloning medium 
complete RPMI1640 medium supplemented with 200 U/ml IL-2 (Proleukin, gift from Roche, 
Basel, Switzerland) was used. 
DC medium was AIM-V Medium (Gibco, Invitrogen) supplemented with 500 U/ml GM-CSF 
(PeproTech, Rocky Hill, NJ, USA) and 104 U/ml IFN-α (Intron A, Essex Chemie AG, Luzern, 
Switzerland). LPS (final concentration 0.5 µg/ml) (E.coli 026.B6, Sigma-Aldrich, Saint Louis, 
USA), TNF-α (final concentration 50 ng/ml) and IFN-γ (final concentration 100 ng/ml) (both 
from PeproTech) were added for the last 24 hrs of culture. 
CTL Assay medium is based on medium 199 (31153026, Invitrogen) containing 2% FCS, 5 
mM HEPES (15630056, Invitrogen), 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin. 
Complete medium 199 containing 20% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 
µg/ml streptomycin, supplemented with fibroblast growth factors (20 ng/ml human acidic 
fibroblast growth factor and 20 ng/ml human basic fibroblast growth factor; both from 
PeproTech) and heparin (0.2 mg/ml; Sigma-Aldrich) was generally used for culturing 
endothelial cells. EC washing medium is based on medium 199 containing 5% FCS, 2 mM L-
glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
Special media for particular experiments are indicated in the corresponding section. 
 
 
 
2.2 Peptides, cytokines, reagents and Abs 
 
The following HLA-A*02 restricted peptides were synthesized as described [164] (generous 
gifts from St. Stevanovic, Tübingen, Germany): GILGFVFTL (Flu(58-66)), FIDSYICQV 
(SMCY(311-319)), the ubiquitously expressed YLLPAIVHI (DDX5(148-156)), and the two 
endothelial cell selective peptides SLLDKIIGA (PTRF(54-64)), and SLSEKTVLL (CD59(106-114)). 
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Peptides were dissolved in DMSO (Sigma-Aldrich) at indicated concentrations and stored at 
4°C.  
The following cytokines were used: GM-CSF (PeproTech, Prod.-Nr. 300-03), IL-2 (Proleukin, 
gift from Roche), IFN-α (Intron A, Essex Chemie AG), IFN-γ (PeproTech, Prod.-Nr. 300-02) 
and TNF-α (PeproTech, Prod.-Nr. 300-01). LPS (E.coli 026.B6) was from Sigma-Aldrich. All 
stock solutions were stored in aliquots at -70°C. 
Calcein-AM (C1430, Molecular Probes, Invitrogen) was dissolved in DMSO at 5 mM and 
stored at -20°C. 
Antibodies were used for flow cytometry, western blot and immunofluorescence. The source, 
specificity and conjugation are shown in Table 3. 
PE-labelled Pro5TM MHC Pentamers for the HLA-A*02-binding peptide SMCY(311-319) were 
purchased from ProImmune (Oxford, UK). 
 
Table 3. Antibodies used for different experiments. 
Antigen Species Conjugate Supplier Cat. No. Usage Titer 
CD3 mouse IgG FITC BD Pharmingen 555332 FC 5µl/tube
CD4 mouse IgG PE BD Pharmingen 555347 FC 5µl/tube
CD4 mouse IgG FITC BD Pharmingen 560133 FC 5µl/tube
CD8 mouse IgG PE BD Pharmingen 555635 FC 5µl/tube
CD8 mouse IgG APC BD Pharmingen 555369 FC 5µl/tube
CD14 mouse IgG PE BD Pharmingen 345785 FC 5µl/tube
CD25 mouse IgG APC BD Pharmingen 560133 FC 5µl/tube
CD31 mouse IgG PE BD Pharmingen 555446 FC 5µl/tube
CD40 mouse IgG PE BD Pharmingen 555589 FC 5µl/tube
CD45 mouse IgG FITC BD Pharmingen 345808 FC 5µl/tube
CD80 mouse IgG PE BD Pharmingen 557227 FC 5µl/tube
CD83 mouse IgG FITC BD Pharmingen 556910 FC 5µl/tube
CD86 mouse IgG FITC BD Pharmingen 555657 FC 5µl/tube
BB7.2 mouse IgG purified gift from P. 
Cresswell, Yale 
University Medical 
School, New 
Haven, USA 
- FC 1:100 
FoxP3 mouse IgG PE BD Pharmingen 560133 FC 5µl/tube
- mouse IgG PE BD Pharmingen 555748 FC 5µl/tube 
- mouse IgG FITC BD Pharmingen 555749 FC 5µl/tube 
- mouse IgG APC BD Pharmingen 554681 FC 5µl/tube 
- mouse IgG purified Serotec mca928 FC 1:100 
mouse IgG goat antiserum FITC Jackson 115-095-003 FC 1:200 
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Table 3. Antibodies used for different experiments (continued). 
Antigen Species Conjugate Supplier Cat. No. Usage Titer 
Beta-1 mouse IgG purified Abcam ab22672 WB 1:1000 
β-Actin mouse IgG purified Sigma-Aldrich A5441 WB 1:80000 
CD59 mouse IgG purified Serotec MCA1054 WB 1:200 
DDX5 goat IgG purified Abcam ab10261 WB 1:750 
LMP-2 rabbit IgG purified Abcam ab3328 WB 1:1000 
LMP-7 rabbit IgG purified Abcam ab3329 WB 1:1000 
PTRF mouse IgG purified BD/Transd. Lab P87520 WB 1:250 
mouse 
IgG 
goat antiserum HRP Jackson 115-035-071 WB 1:4000 
rabbit IgG goat antiserum HRP Jackson P0448 WB 1:1000 
goat IgG rabbit antiserum HRP DAKO P0449 WB 1:2000 
       
Flag mouse IgG purified Sigma F1804 FC, IF,WB 1:50-
250 
vWF rabbit IgG purified DAKO A0082 IF 1:200 
- mouse IgG biotin BD Pharmingen 33812x IF 1:80 
- rabbit IgG biotin Jackson 711-065-152 IF 1:200 
- Streptavidin Cy2 Jackson 016-220-084 IF 1:100 
       
PD-L1 
(B7H1) 
mouse IgG purified eBioscience 16-5983 Inhibition 10µg/ml 
FC: flow cytometry, WB: western blot, IF: immunofluorescence 
 
 
 
2.3 General methods 
 
2.3.1 RNA isolation and RT-PCR 
Total RNA was isolated from 5x106 cells using TRIzol-Reagent (Invitrogen Life Technologies) 
according to the manufacturer’s protocol. After RT (MMLV; Invitrogen Life Technologies) 
cDNA coding for Flu and Flag, respectively, was amplified using the following primers (all 
from Microsynth, Balgach, Switzerland): 5'-ATGGGGAAGGTGAAGGTCGG-3' and 5'-
AGGGATGATGTTCTGGAGAG-3' for GAPDH, 5'-GGGAAGAACACCGATCTTGA-3' and 5'-
CTCCGTTCCCATTAAGAGCA-3' for Flu, 5'-ATCCACGCTGTTTTGACCTC-3' and 5'-
CCTGACGGGACGATA GAGAG-3' for Flag. The PCR amplification of cDNA fragments was 
performed as follows: 1 µl template cDNA, 1 µl dNTP mix (10 mM each, stock solution from 
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Sigma-Aldrich), 1 µl each of upper and lower primer (2.5 µM stock), 1 µl MgCl2 (25 mM, 
Promega, Madison, WI, USA), 1 µl Promega 10xBuffer, 0.1 µl Taq Polymerase (Promega) 
and 4 µl dH20 was added to a final volume of 10 µl. PCR for Flu, Flag and GAPDH cDNA 
was performed with an initial denaturation step at 96°C for 5 min, then 35 cycles with 30 sec 
denaturation at 96°C, 30 sec annealing at 58°C, 1 min elongation at 72°C, followed by the 
final extension for 10 min at 72°C. For agarose gel electrophoresis 3 µl of PCR samples were 
mixed with 1 µl 6x loading buffer (0.25% bromphenol blue, 0.25% xylene cyanol, 30% 
glycerol) and put on a 1.5% agarose gel in 100 ml of 1xTAE running buffer (10 mM Tris-
base, 1 mM EDTA, pH 8.0). 3 µl of a 100 bp ladder (Promega) was loaded into a separate 
slot as molecular weight standard. 80 Volts were applied for about 40 min and then the 
agarose gel was incubated for 15 minutes in dH20 containing 2 µg/ml EtBr. Separated bands 
were visualized using UV light (ChemiIumager 5500, Alpha Innotech).  
 
 
 
2.3.2 Western blot 
Cells (2.5x106) were lysed in 200 µl lysis buffer (20 mM Tris HCl pH 7.5, 150 mM NaCl, 1 mM 
DTT (Roche), 100 µM Na3VO4, 1 mM NaF and 1% Triton-X in dH2O) containing the following 
protease inhibitors (10 µg/ml aprotinin, 10 µg/ml leupeptin (both from Sigma-Aldrich) and 5 
µg/ml pepstatin (AppliChem, Darmstadt, Germany)). Non-reducing conditions were used for 
CD59. PTRF (43.5kD) and DDX5 (68kD) were separated on a 9% and CD59 (19kD) LMP-2 
(24kD), LMP-7 (23kD), and Beta1 (25kD) on a 15% SDS-PAGE, respectively. The proteins 
were transferred onto cellulose nitrate (Protran BA83, Whatman Schleicher&Schüll, Dassel, 
Germany) and blocked in TBS (25 mM Tris, 192 mM Glycin, 20% Methanol) containing 5% 
fat-free milk. The proteins were detected with mAbs specific for PTRF, DDX5, and CD59, 
LMP-2, LMP-7, and Beta-1 (see Table 3). β-Actin was used as a loading control. All antibody 
incubation steps were performed for 60 min at room temperature. After adding the 
peroxidase-conjugated Ab (peroxidase-conjugated goat anti-mouse antibody, peroxidase-
conjugated rabbit anti-goat antibody), the chemiluminescence substrate (Supersignal West 
Pico, Pierce Chemical Company, Perbio Science, Sweden) was added according to the 
manufacturer’s protocol, and a photographic film (Biomax, Eastman Kodak, Rochester, NY, 
USA) was exposed to the membrane and developed (Curix 60, Agfa-Gevaert, Mortsel, 
Belgium). 
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2.3.3 Immunofluorescence staining 
 
Flag staining 
Adherent cells were grown on gelatine-coated cover slips in 6-well plates (BD Falcon, San 
Jose, CA, USA) until the cells were confluent. For suspension cells, 200’000 cells per spot 
were spun down on gelatin/chromalaun-coated glass slides (Cytospin2, Shandon, Waltham, 
USA) at 800 rpm for 8 min [105]. The day before the staining, the cells were washed with ice-
cold PBS (Gibco) and fixed with a mixture of cold acetone and methanol (1:1) for 4 min. 
Afterwards, the cover slips were air dried overnight. The next day, after washing in 
phosphate-buffered saline (PBS; pH 7.4), the cover slips and slides, respectively were 
incubated for 45 min at room temperature (RT) in medium 199 containing 20% FCS to block 
nonspecific protein-binding sites. Then, the slides were washed with RT PBS three times for 
5 min. A mouse anti human Flag tag antibody (1:50) was used to detect endothelial cells. 
After one hour incubation at RT, slides were washed 3 times with PBS. Then, a secondary 
biotinilated anti mouse IgG antibody (1:80) was added for 1 hour at RT. After washing again 
3 times with PBS for 5 minutes, the slides were incubated with a tertiary Streptavidin Cy2-
conjugated Ab (1:100) for one hour at RT. Afterwards, the slides were washed 3 times with 
PBS, and then stained with Hoechst (1:3000, Nr. 33258, Sigma-Aldrich) for 10 min at RT. 
After washing again, the slides were mounted in fluorsave (Calbiochem, Merck Chemicals 
Ltd., Nottingham, UK) and stored at 4°C in the dark until fluorescence microscopy was 
performed.  
 
 
von Willebrand factor staining 
Cells were treated as described for Flag staining. As first antibody a rabbit anti human von 
Willebrand factor antibody (1:200) was used to detect endothelial cells. After washing, a 
secondary biotinilated anti rabbit IgG antibody (1:200) was added for one hour at RT. After 
washing again, the slides were incubated with a tertiary Streptavidin-Cy2 Ab (1:100) for one 
hour at RT. Afterwards, the slides were washed, and then stained with Hoechst (1:3000) for 
10 min at RT and mounted in fluorsave as described before. 
 
 
2.3.4 Peptide-MHC staining by FACS 
For all pentamer stainings 1x106 cells were used. Samples were stained with PE-labelled 
Pro5TM MHC pentamers (ProImmune, 1:20, total volume 100µl) for 10 min at room 
temperature in the dark, then washed with PBS containing 2% FCS. In a second staining 
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step, the cells were incubated with saturating amounts of APC-conjugated anti-CD8 mAb 
(see Table 3) for 20 min on ice for subset identification. The cells were then washed two 
more times with PBS containing 2% FCS. Propidium iodide (PI, final conc. 5µg/ml, Sigma-
Aldrich) was added as a vital dye prior to data acquisition. Analysis was performed on a 
CyAn™ ADP FACS instrument using Summit Software (Dako Cytomation, Glostrup, 
Denmark). The lymphocytes were gated and 5x105 (CTL clones) aliving (PI negative) 
lymphocytes were acquired and analyzed.  
 
 
 
2.4 HLA-A*02 binding 
 
2.4.1 T2 peptide binding assay 
A T2 binding assay was used as described [165]. The HLA-A*02 restricted peptides 
GILGFVFTL (Flu(58-66)), FIDSYICQV (SMCY(311-319)), SLLDKIIGA (PTRF(56-64)), SLSEKTVLL 
(CD59(106-114)) and YLLPAIVHI (DDX5(148-156)) (generous gift from St. Stevanovic, University of 
Tübingen, Tübingen) were dissolved in DMSO at a concentration of 1mg/ml (Table 4). TAP-
deficient T2 cells were incubated overnight at 37°C with 5x10-5M peptide in complete RPMI 
1640 supplemented with 2.5% FCS. Cells were washed and surface expression of HLA-A*02 
was then determined by flow cytometry using BB7.2 mAb (1:100, gift from Peter Cresswell, 
Yale Medical School, New Haven CT, USA) and an isotype control Ab, respectively, followed 
by incubation with FITC-labelled goat anti mouse IgG secondary Ab (1:100). All incubations 
were strictly performed at a temperature of 4°C. Data acquisition was performed on a CyanTM 
ADP FACS instrument using Summit Software (Dako). Per sample, 1x105 cells were 
acquired and analyzed. The ∆ mean fluorescence intensity (∆MFI) was calculated by 
subtracting the MFI with isotype control Ab from the MFI with BB7.2 mAb. The peptide 
binding index was calculated as ∆MFI with peptide/∆MFI without peptide [166]. 
 
 
2.4.2 Peptide competition assay 
Peptide concentrations were adjusted according to the results of a peptide competition 
assay. This experiment was performed with the help of C. S. Chennakesava in our lab. T2 
cells were loaded with 10-8M Flu(58-66) and different concentrations of SMCY(311-319), DDX5(148-
156), PTRF(56-64), and CD59(106-114), respectively, ranging from 10-4M to 10-12M were added. 
Cells were incubated overnight at 37°C in complete RPMI 1640. The next day, a calcein-
release cytotoxicity assay was performed as described below and the concentration of 
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peptide in the presence of 10-8M Flu peptide was determined at which target cell killing by 
Flu(58-66)-specific CTL was inhibited by 50%. Peptide concentrations of DDX5(148-156), PTRF(56-
64), and CD59(106-114) were adjusted by normalization to the competing concentration of 
SMCY(311-319), which was set to be 1. Thus, for DDX5(168-176) a 2.4-fold higher concentration, 
for PTRF(54-64) a 4.4-fold higher concentration and for CD59(311-319) a 8-fold higher 
concentration was calculated (Table 4). 
 
Table 4. Peptide concentrations. 
 
peptide 
 
MW 
normal adjusted 
stock 
concentration 
molar 
concentration 
stock 
concentration 
molar 
concentration 
Flu(58-66)  965.6  1 mg/ml  1.04 mM - - 
SMCY(311-319)   1087  1 mg/ml  0.92 mM - - 
DDX5(168-176)  1038  1 mg/ml  0.96 mM 2.4 mg/ml 2.3 mM 
PTRF(56-64)  928.6  1 mg/ml  1.08 mM 4.4 mg/ml 4.7 mM 
CD59(106-114)  988.6  1 mg/ml  1.01 mM 8 mg/ml 8.1 mM 
 
 
 
2.4.3 Decay and half-life of the peptide-MHC class I-complex 
For the determination of half-life of the HLA-A*02-peptide complexes, T2 cells were loaded 
with peptide in adjusted concentrations overnight at 37°C in complete RPMI 1640 
supplemented with 2.5% FCS. The next day, peptide was washed away and the cells were 
incubated again at 37°C. At indicated time points (0h, 2h, 6h, 24h) the cells were stained for 
HLA-A*02 as described above and the fluorescence index was analyzed by flow cytometry. 
 
 
 
2.5 Cell lines 
 
2.5.1 Culture of EC, BLC, CC 
All studies involving primary human cell lines and tissues were approved by the institutional 
ethical review board. Human umbilical vein endothelial cells (HUVEC) were isolated from 
umbilical cords by enzymatic digestion as described previously [121]. EC were cultured in 
complete medium 199 containing 20% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 
µg/ml streptomycin (all from Invitrogen), supplemented with fibroblast growth factors (20 
ng/ml human acidic fibroblast growth factor and 20 ng/ml human basic fibroblast growth 
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factor; both from PeproTech) and heparin (0.2 mg/ml; Sigma-Aldrich). The HLA-A*02-
positive, male EBV-transformed B cell line JY, the female TAP-deficient T2 cell line (both gifts 
from A. Cerny, University of Bern, Bern, Switzerland), the HLA-I negative K562 cell line and 
the colon carcinoma cell line LS174 (provided by G. Spagnoli, University of Basel, Basel, 
Switzerland) were cultured in complete RPMI 1640 (Invitrogen) containing 10% FCS, 2 mM 
L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
 
 
2.5.2 Isolation of peripheral blood mononuclear cells (PBMC) 
Buffy coats were obtained from healthy HLA-A*02 positive blood donors (Blutspendezentrum 
SRK, Basel, Switzerland). PBMC were isolated by Ficoll gradient separation (Lymphoprep, 
Axis-Shield, Dundee, UK) according to the manufacturer’s instructions, washed twice with 
HBSS, suspended in ice-cold freezing medium (90% low endotoxin FCS (Invitrogen Life 
Technologies) containing 10% DMSO) and stored in liquid nitrogen. On average, 
7.38x108±2.31x108 cells were isolated per buffy coat. After thawing, viability of PBMC was 
>95% as judged by trypan blue staining and dye exclusion. In male donor PBMC, a 84 bp 
fragment of the male-specific DFFRY gene [167, 168] was amplified from genomic DNA 
using the following primers (all from Microsynth): 5'-AACTCACCTCCAACACATACTCCAC -
3' and 5'-TTCATGATGAAATCTGCTTTTTGT TT -3'. 
 
 
 
Figure 2. Gender confirmation of donors. Gender of male and female donors 
was confirmed by amplification of a 84 bp fragment of the male-specific 
DFFRY gene. 
 
 
2.5.3 Monocyte-derived dendritic cell (DC) preparation  
Monocytes were isolated from PBMC by negative selection using magnetic cell sorting by 
autoMACS® according to the manufacturer’s protocol (Monocyte Isolation Kit II, Miltenyi 
Biotec, Bergisch-Gladbach, Germany). 2x106 CD14+ monocytes/well were seeded on 24-well 
plates (BD Falcon, Prod.-Nr. 353047) and cultured for 3 days in AIM-V medium (Invitrogen) 
supplemented with 500 U/ml GM-CSF (PeproTech) and 104 U/ml IFN-α (Intron A, Essex 
Chemie AG) [169, 170]. To induce final DC maturation, LPS (E. coli 026.B6, Sigma-Aldrich), 
TNF-α (Pepro-Tech, final concentration 50 ng/ml) and IFN-γ (Pepro-Tech, final concentration 
100 ng/ml) were added for the last 24 hrs of culture. DC differentiation was confirmed by 
visual inspection (intense cluster formation) and by FACS. 
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2.5.4 Flow cytometry analysis of monocytes and dendritic cells 
For flow cytometry staining the following antibodies were used: directly conjugated antibodies 
against CD14-PE, CD80-PE, CD86-FITC, CD40-PE, CD83-FITC and CD3-FITC (see Table 
3). Mouse IgG-PE and IgG-FITC were used as control. 5x105 monocytes or DC, respectively, 
were washed once with PBS containing 1% BSA (Fluka, Saint Louis, USA) and incubated 
with the antibodies (final concentration 1:20). For 30 min at 4°C. Cells were washed again 
twice and then fixed in 2% paraformaldehyde in PBS. Analysis was performed on a CyAn™ 
ADP FACS instrument using Summit Software (both from Dako). For dendritic cell 
differentiation, total leukocytes were gated according to forward (FSc) and sideward scatter 
(SSc). And for each staining condition, 1x105 cells were acquired and analyzed. 
 
 
2.5.5 Induction of peptide-specific CTL lines  
Monocyte-derived DC were harvested with 1mM EDTA in HBSS (pH 7.5) for 30 min at 37°C, 
pooled and washed once with complete RPMI 1640 supplemented with 2.5% FCS. Cells 
were resuspended at 1x106 cells/ml in complete RPMI 1640-AB containing 10% heat-
inactivated human AB serum (Blutspendezentrum SRK, Basel, Switzerland) instead of FCS 
and were pulsed with peptide in adjusted concentrations (10-5M for Flu(58-66), 10-5M for 
SMCY(311-319), 2.4x10-5M for DDX5(148-156), 4.4x10-5M for PTRF(56-64) and 8x10-5M for CD59(106-
114)) for 2 hours at 37°C. The peptide-pulsed DC were washed twice with complete RPMI 
1640 supplemented with 2.5% FCS, and 4x105 DC were used at a ratio of 1:10 to stimulate 
4x106 CD8+ T cells in 1 ml complete RPMI 1640-AB in 24-well plates. The responder cells 
were isolated from autologous PBMC (CD8+ T Cell Isolation Kit II, Miltenyi Biotec). CD8 cell 
isolates were >85% pure. All cultures were maintained at 37°C in 5% CO2 humidified air. IL-2 
(Proleukin, gift from Roche, final concentration 20 U/ml) was added on day 3 of the induction 
culture. CTL lines were restimulated in weekly intervals with autologous irradiated (3000 rad) 
PBMC pulsed with peptide in adjusted concentrations and cultured in complete RPMI 1640-
AB with 50 U/ml IL-2. After 2 weeks and then in weekly intervals, the CTL lines were tested 
for peptide-specific cytotoxicity using peptide-pulsed T2 cells as targets in a calcein-release 
assay (see below). For selected induction cultures, a blocking antibody against human PD-
L1 (eBioscience, San Diego, USA, final concentration 10µg/ml) or the pancaspase inhibitor z-
VAD (BD Bioscience Pharmingen, final concentration 50µM) were used at indicated 
concentrations to promote outgrowth of CTL [98, 171]. 
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2.5.6 Induction of CTL clones by limiting dilution 
Peptide-specific CTL lines that showed >70% of peptide-specific cytotoxic activity after 5 
weeks were chosen for cloning by limiting dilution as published [103]. In brief, the CD8+ T 
lymphocytes were counted and suspended in complete cloning medium (complete RPMI 
1640 supplemented with 200 U/ml IL-2, and 1 µg/ml PHA-L (Oxoid AG, Pratteln, 
Switzerland)) containing 500,000/ml irradiated (3000 rad) PBMC and 25,000/ml mitomycin C-
treated (Roche, final concentration 50 µg/ml) JY cells. These cell suspensions were 
distributed in 100 µl/well to round-bottom 96-well plates, resulting in input CD8+ T cell 
numbers of 100, 10, and 1 per well. After 1 week, microcultures were fed by adding 100 
µl/well incomplete cloning medium (without PHA and feeder cells). Expanding clones were 
identified by visual inspection. Microcultures that grew at the frequency corresponding to 
clonal growth and single hit kinetic were expanded and tested for peptide-specific lysis in a 
calcein-release assay [105]. The CTL clones were kept in culture in incomplete cloning 
medium until restimulation that was necessary on average every 3 weeks. Restimulation was 
performed by adding 5x106 CTL into 20 ml complete cloning medium. 
 
 
2.5.7 Induction of alloreactive CTL lines 
PFA-fixed T2 cells loaded with PTRF(56-64) and CD59(106-114) were used as stimulator cells for 
CTL differentiation from CD8 preCTL. T2 cells were taken from culture and loaded with 
PTRF(56-64) and CD59(106-114) in adjusted concentrations (see 2.5.5). After 2 hrs incubation, 
cells were washed with complete RPMI 1640 supplemented with 2.5% FCS and then fixed 
with 1% paraformaldehyde for 10 min at room temperature. Afterwards, cells were 
extensively washed, and resuspended in complete RPMI 1640-AB in a 96-well round-bottom 
plate at 104 cells per well. Cocultures were initiated by addition of CD8+ T cells. Purified 
CD8+ T cells (CD8+ T Cell Isolation Kit II, Miltenyi Biotec) were suspended in RPMI 1640-
AB and added at 105 cells per well to the stimulator cells. The cocultures were fed with fresh 
medium containing IL-2 at a final concentration of 50 U/ml after 3 days and restimulated 
weekly. For restimulation, 150 µl of supernatant per well was removed from the 
microcultures. Fresh medium containing IL-2 (50 µl/well) was added, and the CD8+ T cells 
were transferred to fresh PFA-fixed peptide loaded T2 cells. After 2 weeks, the cocultures 
were tested weekly for peptide-specific lysis in a calcein-release cytotoxicity assay (see 
below).  
 
 
 38 
2.5.8 Calcein release-based cytotoxicity assay 
 
CTL assay with B lymphoblastoid cells as targets 
CTL mediated target cell lysis was measured by a calcein-release assay as described [172]. 
Target cells (T2 or JY cells) were incubated for 30 min at 37°C with 10 µM calcein-AM 
(Molecular Probes, Invitrogen). Cells were then washed and bleached for 30 min at 37°C in 
complete RPMI 1640. After washing twice, target cells were suspended in assay medium 
(medium 199, 2% FCS, 5 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml 
streptomycin), counted and transferred to 96-well, round-bottom plates (Falcon, BD 
Biosciences) at 2x104 cells/well. CTL were washed, counted, and added to the calcein-
loaded target cells at a E:T ratio of 10:1 (final volume 200 µl/well). Spontaneous release (SR) 
was determined by adding assay medium to the target cells; maximum release (MR) was 
obtained by target cell lysis (lysis buffer: 50 mM sodium borate in 0.1% Triton X-100 (both 
from Sigma-Aldrich), pH 9.0). Then, the assay plates were centrifuged with 470g for 4 min at 
room temperature. After incubation for 2 hrs at 37°C, 75 µl of supernatant was carefully 
removed and transferred to a 96-well, flat-bottom plate. Released calcein was measured in a 
fluorescence multiwell plate reader (SpectraMax GeminiXS; Molecular Devices; excitation 
wavelength, 485nm; emission wavelength 538nm). Percent specific lysis was calculated as 
(sample release – SR)/(MR – SR) X 100%.  
 
 
CTL assay with endothelial cells as targets 
Adherent EC grown to confluency in 96-well flat-bottom plates (Falcon, BD Biosciences) 
were loaded for 30 min at 37°C with 20 µM calcein-AM (Molecular Probes, Invitrogen) in 
medium 199. Cells were then washed and bleached for 2 hrs at 37°C in complete medium 
199. Cells were washed twice with complete medium 199, then assay medium was added. 
CTL were washed, counted, and added to the calcein-loaded target cells at a E:T ratio of 
10:1 (final volume, 200 µl/well). For preparation of SR and MR wells and measurement see 
above.  
 
 
2.5.9 Treg marker analysis by flow cytometry 
The induction cultures were analyzed for the presence of Tregs by staining for the Treg 
markers Foxp3, CD4 and CD25 (FoxP3 staining bundle kit, BD Pharmingen). Staining was 
performed according to the manufacturer’s protocol. In brief, 1x106 cells per staining were 
washed with PBS containing 2% FCS and stained with the conjugated surface markers CD4 
and CD25 for 20 min at room temperature. Then, samples were washed with PBS containing 
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2% FCS and fixed with 1x Human FoxP3 Buffer A for 10 min at room temperature. Cells 
were washed again and permeabilized with 1x Human FoxP3 Buffer C for 30 min at room 
temperature. After permeabilization the cells were washed twice and incubated with 
conjugated FoxP3 antibody for 30 min at room temperature. Then, the samples were 
washed, resuspended in wash buffer and analyzed immediately. 
 
 
2.5.10 Stimulation with proinflammatory cytokines 
 
Cytokine stimulation for CTL assays or flow cytometry 
EC or BLC were cultured in culture medium alone or in medium containing 100 ng/ml IFN-γ 
and 50 ng/ml TNF-α overnight. The next day, cells were washed to remove cytokines and 
CTL assay or flow cytometry experiments were performed as described above. 
 
Induction of immunoproteasomes  
EC, JY, T2 and CC cells were cultured in culture medium alone or in medium containing 100 
ng/ml IFN-γ for 18 hrs. Cells were lysed and the lysates were analysed by western blot for 
the occurrence of the constitutive proteasome and the induction of immunoproteasomes as 
described in 2.3.2. 
 
 
 
2.6 Transduction of EC and JY with FluM1 
 
2.6.1 Transfection of GP-293 cells 
The Retro-X Universal Packaging System (Clontech, Mountain View, CA, USA, Nr. 631530) 
was used for retrovirally transduction of primary EC and JY cells. The flag-tagged retroviral 
construct of the full length cDNA encoding influenza matrix protein M1 (kind gift from G. 
Kochs, Germany) was cloned into the bicistronic expression vector pQXIN (done by C. S. 
Chennakesava) (Figure 3). A neomycin resistance was included for selection. The host cell 
line GP-293 was seeded the day before transfection in collagen-coated 6-well plates at 
200.000 cells per well and cultured in GP-2 medium (DMEM (high glucose from Invitrogen) 
supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml 
streptomycin, and 5mM sodium pyruvate) at 37°C. The next day, the medium was changed 
into 2 ml prewarmed GP-2 medium containing 25 µM chloroquine (Sigma-Aldrich) per well. 
The pantropic viruses were prepared as follows: 6 µg of the retroviral vector pVSV-G and 6 
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µg of the carrier vector pQM1IN (pQXIN vector containing the FluM1 sequence) per 
transfection were washed with sterile H2O. Then, 2M CaCl2 and 2xHBS (8.0 g NaCl, 0.37 g 
KCl, 201 mg Na2HPO4•7H2O, 5.0 g HEPES/500 ml H2O, pH 7.0) were added quickly and 
mixed well with the DNA complexes. 1 ml of the DNA mixture was added to each well 
dropwise. The cells were incubated at 37°C. After 18 hrs, the medium was changed into 
fresh GP-2 medium and the cells were cultured at 32°C for 72 hrs.  
 
 
Figure 3. FluM1 vector map. (A) shows the pQM1IN carrier vector (pQXIN vector containing the FluM1 
vector), (B) multiple cloning site with inserted FluM1 sequence under a CMV promoter flanked by a 
Flag-tag and Neomycin resistence. 
 
 
2.6.2 Infection of endothelial cells  
A day before infection very early passage EC were seeded in a 15x60 mm petri dish at 
240.000 cells in complete medium 199. The viral supernatants from GP-293 cells were 
collected after 72 hrs, pooled and polybrene (8 µg/ml) was added to enhance the viral 
infection effectivity. Supernatants were centrifuged and filtered (Sartorius, Göttingen, 
Germany, 17598 K 0.45mm Minisart Nylon). The medium of the endothelial cells was 
replaced by 2.5 ml viral supernatant and cells were cultured at 37°C. After 24 hrs the viral 
supernatants were replaced by normal complete medium 199 and cells were left for 48-72 
hrs. The process of infection was repeated twice by infecting the EC at a splitting ratio of 1:3. 
After three serial infections transduced cells were put under selection by adding selection 
medium (complete medium 199 with 600 µg/ml G418 (Gibco)). After selection, cells were 
splitted at a ratio of 1:2 and always kept in selection medium. 
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2.6.3 Infection of JY cells 
The viral supernatants from GP-293 cells were collected after 72 hrs, pooled and polybrene 
(8 µg/ml) was added to enhance the viral infection effectivity. Supernatants were centrifuged 
and filtered (Sartorius, 17598 K 0.45mm Minisart Nylon). 200.000-250.000 JY cells were 
spun down and resuspended in 1ml of the viral supernatant. Cells were centrifuged for 90 
min at 1258g at 32°C. Then, the supernatant was discarded and the cells were resuspended 
in 1 ml complete RPMI 1640 in a 24-well plate and cultured at 37°C. Infection of JY was 
accomplished by three serial infections and JY cells were selected with 1 mg/ml G418 per 
2x106 cells. 
 
 
2.6.4 Proteasome inhibition 
Transduced EC-FluM1 cells were grown confluent in 10x20 mm petri dishes in complete 
medium 199. Cells were washed with HBSS (Invitrogen) and 1 µM clasto-lactacystein β-
lactone (Prod.-Nr. 426102, Calbiochem) was added as irreversible proteasome inhibitor in 
complete medium 199 for indicated time points (0h, 2h, 4h, 6h, 24h). For some experiments, 
100 ng/ml IFN-γ and 50 ng/ml TNF-α were added at the same time points as the proteasome 
inhibitor. For cytotoxicity assay, EC were washed with HBSS once and then detached with 
trypsin/EDTA (Nr. 25300054, Invitrogen). After washing twice with EC washing medium, EC 
were resuspended in medium 199 and loaded with 20 µM calcein. Then, the cytotoxicity 
assay was performed as described above. 
 
 
 
2.7 siRNA knockdown of abundant EC peptides 
 
The following siRNAs (40 µM stock concentrations) from Microsynth were used: mock siRNA 
5’-AGGUAGUGUAAUCGCCUUGtt-3’; CD59 siRNA 5’-GAAGUCUAAGAGUGAAGUAtt-3’; 
PTRF siRNA 5’-GAGGAAAGAUUGAAUCCUAT-3’; DDX5 siRNA 5’-GCAGAUAGAAUG 
CUUGAUAtt-3’. Early passage EC were seeded one day before transfection at 100.000 cells 
per well in medium 199-P/S (complete medium 199 without penicillin/streptomycin) in a 
gelatine-coated 6-well plate. The next day, the medium was replaced with 2.5 ml prewarmed 
medium 199-P/S. RNA complexes were prepared as follows (volumes for one well of a 6-well 
plate): 250 µl of room temperatured OptiMEM I Glutamax™ medium (Gibco) were mixed with 
15 µl of 2 µM siRNA (final concentration 10 nM) in a RNAse-free eppendorf tube to prepare 
solution A. Then, for solution B 250 µl of OptiMEM were mixed with 5 µl of RNAiMAX 
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(Lipofectamine RNAiMAX transfection reagent, Invitrogen) in a second RNAse-free tube. 
Solutions A and B were slowly mixed together and incubated for 10-20 min at room 
temperature for complexing of siRNA. Then, the complexes were added dropwise to the cells 
without further pipetting and the cells were incubated at 37°C. The medium was changed 
after 16 hours and the cells incubated for indicated time points. Cells were either lysed as 
described in section 2.3.2 and analyzed by Western blot for knockdown of proteins or directly 
used for cytotoxicity assays and flow cytometry. 
 
 
 
2.8 Statistics 
 
Mean values between groups were compared using the student's t test. Tests were 
performed with SPSS 15.01 software (SPSS Inc, Chicago, USA). Unless indicated otherwise, 
mean ± standard deviation of replicates are shown. 
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3. Results 
 
 
3.1 Comparison of HLA-A*02-restricted peptide presentation 
between EC and BLC 
 
3.1.1 Characterization of the endothelial HLA-A*02-presented peptide repertoire 
In a previous study in our lab (performed with the help of M. Keller in collaboration with S. 
Stevanovic, University of Tübingen) the endothelial and leukocyte-derived peptide profile 
from three healthy HLA-A*02 positive male individuals was examined. Endothelial cells (EC) 
and B-lymphoblastoid cells (BLC) were grown side-by-side under comparable conditions. 
The entire pool of peptides bound to endothelial or leukocyte MHC class I molecules was 
isolated, fractionated and the individual components were characterized by mass 
spectrometry. By this method, the most abundant MHC class I ligands of a cell can be 
identified. The amino acid sequences of the HLA-A*02 restricted peptides were used for 
sequence homology analysis and the source proteins from which these peptides derive were 
identified (Table 5). It is striking that endothelial cells and leukocytes shared only two out of 
the twenty peptides. Cyclin I [173] and DEAD box polypeptide 5 (DDX5) are the source 
proteins for the two shared peptides, and both are ubiquitously expressed in the body. Of the 
five peptides found on endothelial cells but not on leukocytes, none was novel but all were 
previously identified in at least one or more other tissues or cell lines (Table 5). Two of them 
were consistently identified in all the three EC donors analyzed in this study. The proteins 
from which these two peptides arise are polymerase I and transcript release factor (PTRF), 
and the complement inhibitor CD59. Both peptides have been isolated previously from other 
epithelial tissues, particularly renal cancer cell lines. Yet, the relative amounts of PTRF and 
CD59 derived peptides were remarkably higher in EC compared to other cell lines and 
tissues from which these peptides have been isolated previously. In EC, the two peptides 
were repetitively identified as the most abundant HLA-A*02 ligands. Therefore, PTRF(56-64) 
and CD59(106-114) were chosen as representative endothelial-selective peptides and DDX5(168-
176) as a ubiquitously expressed control. 
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Table 5. HLA-A*02-restricted peptides isolated from syngeneic EC and BLC. 
 
A. Peptides isolated from human umbilical cord blood-derived B lymphoblastoid cells (BLC) 
 
B. Peptides isolated from human umbilical vein endothelial cells (HUVEC) 
1) peptides were identified by tandem mass spectrometry. 
n.d. - not detectable. Samples where a peptide was absent respectively below the detection limit of the 
mass spectrometer. 
 
 
Sequence1) GeneID Protein 3rd party BLC 
YLLPAIVHI 1655 or 10521 DDX box 5 or 17 5 
VLIPKLPQL 94103 ORM1-like 3 4 
ALSDHHIYL 226 aldolase A, fructose-bisphosphate 2 
SIIGRLLEV 5499 protein phosphatase 1 alpha 3 
LLDRFLATV 10983 cyclin I 1 
FIIQGLRSV 3117 or 318 MHC-II, DQ alpha 1 or 2 2 
FLDPRPLTV 1545 cytochrome P450, 1B1 n.d. 
Sequence1) GeneID Protein 3rd party BLC 
SLLDKIIGA 284119 polymerase I and transcript release factor n.d. 
SLSEKTVLL 966 CD59 molecule complement regulatory 
protein 
n.d.  
TLADIIARL 57523 KIAA1305 n.d.  
NLAEDIMRL 7431 vimentin n.d.  
YLPEDFIRV 3656 interleukin-1 receptor-associated kinase 2 n.d.  
YLLPAIVHI 1655 or 10521 DDX box 5 or 17 5 
NLLPKLHIV 1192 or 25932 chloride intracellular channel 1 or 4 3 
LLIENVASL 2876 glutathione peroxidase 1 3 
ILTDITKGV 1938 eukaryotic translation elongation factor 2 3 
TLSDLRVYL 140809 sulforedoxin 1 homolog 2 
LLGPRLVLA 10972 transmembrane emp24-like trafficking 
protein 10 
2 
QLIDKVWQL 6397 SEC14-like 1 1 
LLDRFLATV 10983 cyclin I 1 
SLLDRFLATV 10983 cyclin I 1 
LLAAWTARA 351 amyloid beta precursor protein 1 
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3.1.2 Comparison of source protein expression in EC and BLC 
The most obvious explanation for the preferential representation of MHC class I bound 
PTRF(56-64)  and CD59(106-114) on vascular endothelial cells would be the strong expression of 
PTRF and CD59 genes. Therefore, we compared levels of the source proteins DDX5, PTRF, 
and CD59 in EC and syngeneic EBV-immortalized BLC from the same individual as the EC, 
in the HLA-A*02 positive BLC line JY, in TAP deficient T2 cells and in LS174 colon cancer 
cells (Figure 4). PTRF was expressed exclusively in EC and was not found in any other cell 
line analyzed (Figure 4). CD59 was expressed in EC and in two BLC lines, but not in LS174 
colon cancer cells. However, the expression level of CD59 in EC was extraordinary strong 
compared to the BLC (Figure 4). DDX5, the ubiquitously expressed gene that is the source of 
the allotypic reference peptide presented at large quantities on the HLA-A*02 molecules of 
most tissues [174], was present in all cell lines analyzed at similar levels (Figure 4). BLC and 
EC both expressed CD59 protein and therefore the vast abundance of CD59(106-114) peptide 
on EC compared to BLC cannot be explained by an endothelial cell-specific gene 
expression. Additional factors such as CD59 protein synthesis and/or degradation rate may 
be involved in efficient presentation of this peptide on EC. 
 
 
Figure 4. Cellular representation of source proteins 
that contain the HLA-A*02 presented endothelial 
peptide sequences. Whole cell lysates were used for 
western blot obtained from cultured human umbilical 
vein endothelial cells (EC), B lymphoblastoid cells 
(BLC), the B-cell line JY, T2 cells, and the colon 
carcinoma cell line LS174 and analyzed for the 
presence of the proteins PTRF, CD59 and DDX5. β-
Actin was used as loading control. 
 
 
3.1.3 Comparison of proteasome components in EC and BLC  
Proteins are degraded by the proteasome into antigenic peptides. The constitutive 
proteasome consisting from two outer rings with seven α subunits and two inner rings with 
seven β subunits is expressed in most cells. In addition, there exists also a second 
proteasome type, the immunoproteasome. It has been shown that the immunoproteasome 
can be induced by IFN-γ in some cells which leads to the transcription and translation of the 
three immunoproteasome subunits β1i (LMP2), β2i (MECL-1), and β5i (LMP7) [175]. The 
immunoproteasomes differ from constitutive proteasomes in qualitative and quantitative 
aspects of their proteolytic activity [142] and they have shown to be important for the 
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generation of CD8+ T cell epitopes during viral infections and inflammation [144]. We wanted 
to compare the expression of the constitutive proteasome and the immunoproteasome in EC 
and BLC. Therefore, we established a western blot for the constitutive proteasome subunit 
beta-1 and the two immunoproteasome subunits LMP-2 and LMP-7 and compared EC with 
the BLC line JY, T2 cells and LS174 colon cancer cells (Figure 5). We found in resting EC 
only expression of the beta-1 subunit of the constitutive proteasome and not of the 
immunoproteasome subunits, whereas in resting JY cells also the immunoproteasome 
subunits LMP-2 and LMP-7 were expressed (Figure 5A). T2 cells and the colon carcinoma 
cell line LS174 expressed also only the constitutive proteasome. However, after stimulation 
with IFN-γ overnight, expression of the two immunoproteasome subunits LMP-2 and LMP-7 
could be induced in EC (Figure 5B). 
 
 
Figure 5. Expression of the constitutive and immunoproteasome. Whole cells lysates from EC, JY, T2 
and LS174 cells were analyzed by western blot for the expression of the constitutive proteasome 
subunit beta-1 and the two immunoproteasome subunits LMP-2 and LMP-7, respectively. (A) Analysis 
of proteasome expression in resting cells, (B) expression in cells after stimulation with IFN-γ overnight. 
 
 
3.1.4 Characterization of the HLA-A*02 binding properties of the abundant endothelial 
peptides 
 
SYFPEITHI based algorithm (https://syfpeithi.de) 
In a next step, the binding properties of the abundant endothelial peptides were examined. 
The assignment of PTRF(56-64) and CD59(106-114) to the specific MHC class I allotype HLA-A*02 
and the calculation of the HLA-A*02 binding strength was performed according to the 
software of the HLA ligand database SYFPEITHI 49 (https://syfpeithi.de) and compared with 
the known HLA-A*02 restricted peptides Flu(58-66) and SMCY(311-319) as positive controls and 
the ubiquitously expressed peptide DDX5(168-176) (Table 6). For the five peptides binding 
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scores between 24 and 30 were predicted (maximal binding score = 36) with SMCY(311-319) as 
the weakest binder and Flu(58-66) and DDX5(168-176), respectively, as the strongest. The binding 
of the endothelial peptides PTRF(56-64) and CD59(106-114) was predicted in between.  
 
Table 6. SYFPEITHI binding score 
Flu(58-66 GILGFVFTL 30 
SMCY(311-319) FIDSYICQV 24 
DDX5(168-176) YLLPAIVHI 30 
PTRF(56-64) SLLDKIIGA 25 
CD59(106-114) SLSEKTVLL 29 
 
 
Peptide affinity for HLA-A*02: T2 binding and peptide competition assay 
To confirm the predicted values of the SYFPEITHI algorithm the peptides were subsequently 
tested for HLA-A*02 binding by an assay that is based on the stabilization of HLA-A*02 
molecules by binding of exogenously added peptide, the T2 peptide binding assay [165]. 
TAP-deficient T2 cells were loaded with 10-5M peptide overnight and surface expression of 
HLA-A*02 was then determined by flow cytometry. We analyzed the binding for the 
endothelial peptides PTRF(56-64) and CD59(106-114), and for DDX5(148-156) as ubiquitously 
expressed peptide. Further, we used the low abundant SMCY(311-319) as control. The 
fluorescence index was calculated as ∆mean fluorescence intensity (∆MFI) with peptide / 
∆MFI without peptide [166]. The fluorescence index was set to 1 for T2 cells without peptide. 
SMCY(311-319) was the strongest binder, increasing the fluorescence index about 3-fold 
(3.18±0.2) (Figure 6A). DDX5(168-176) showed a similar binding as SMCY(311-319) with a 
fluorescence index of 2.92±0.1. In contrast to the prediction of the SYFPEITHI algorithm, 
PTRF(56-64) and CD59(106-114) both showed a very weak binding with only a small increase in 
HLA-A*02 expression (2.24±0.1 and 1.41±0.03, respectively).  
To confirm the differences in binding a functional assay was performed. In the peptide 
competition assay, the concentration of peptide in the presence of 10-8M Flu(58-66) peptide 
was determined at which target cell killing by Flu(58-66)-specific CTL was inhibited by 50% 
Therefore, T2 cells loaded with 10-5M Flu(58-66) were incubated with different concentrations of 
the peptide of interest ranging from 10-4 to 10-12M. Correlating with the results of the T2 
binding assay, we found that for SMCY(311-319) a 0.27±0.15, for DDX5(148-156) a 0.62±0.51, for 
PTRF(56-64) a 1.13±0.92 and for CD59(106-114) a 2.07±1.14 fold higher peptide concentration 
was necessary to reduce the Flu(58-66)-specific lysis to 50% (Figure 6C). According to these 
results the peptide concentrations were normalized to the competing concentration of 
SMCY(311-319) which resulted in a 2.4-fold higher concentration for DDX5(148-156), 4.4-fold for 
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PTRF(56-64) and 8-fold for CD59(106-114). Then, the T2 binding assay was performed again with 
the adjusted peptide concentrations (Figure 6B) and a similar surface positivity of HLA-A*02 
for all four peptides could be detected (fluorescence indexes: SMCY(311-319) 2.38±0.1, 
DDX5(168-176) 2.91±0.2, PTRF(56-64) 2.45±02, CD59(106-114) 2.58±0.1) (Figure 6B). 
 
 
Figure 6. HLA-A*02 binding and peptide competition assay. The T2 peptide binding assay was 
performed for 4 different allo- and autopeptides (SMCY(311-319), DDX5(148-156), PTRF(56-64) and CD59(106-
114)) and analyzed by flow cytometry. The fluorescence index was calculated as ∆ mean fluorescence 
intensity (∆MFI) with peptide / ∆MFI without peptide. (A) shows the fluorescence index and typical 
histograms with 10-5M peptide concentrations and (B) with peptide concentrations adjusted to binding 
differences calculated from peptide competition assays. (C) The peptide competition assay shows the 
peptide concentration (x10-5M) in the presence of 10-8M Flu(58-66) at which target killing by Flu(58-66)-
specific CTL was inhibited by 50%. 
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Decay and half-life of peptide-MHC complex 
Next, the decay and half-life of the peptide-HLA-A*02 complexes were determined by 
measuring the HLA-A*02 binding at indicated time points. Therefore, T2 cells were loaded 
with peptide in adjusted concentrations for 24 hrs. Then, unbound peptide was washed away 
and HLA-A*02 binding was measured by flow cytometry at different time points (0h, 2h, 6h, 
24h). SMCY(311-319), DDX5(168-176), and PTRF(56-64) showed similar kinetics with half-lives 
between 5.2 and 7 hrs (Figure 7). In contrast, the half-life of CD59(106-114) was only 2.8 hrs 
and very short compared to the other peptides indicating an unstable peptide-MHC class I 
complex (Figure 7). 
 
 
Figure 7. Half-life of HLA-A*02 bound peptides. T2 cells were loaded with the peptides (SMCY(311-319), 
DDX5(148-156), PTRF(56-64) and CD59(106-114)) in adjusted concentrations according to the peptide 
competition assay and peptide binding was analyzed by flow cytometry at indicated time points (0h, 
2h, 6h, 24h). 
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3.2 Immunogenicity of abundant endothelial cell-selective peptides 
 
 
3.2.1 Induction of self-reactive CTL 
 
Characterization of monocyte-derived DC as antigen-presenting cells 
CD14+ monocytes (purity 78±8.8%) were maturated in vitro into dendritic cell (DC) lines that 
were used as antigen-presenting cells. These cells were analyzed for the expression of 
monocyte- and DC-specific markers (Figure 8). They lost the LPS receptor CD14 (20-fold 
decrease in DC compared with monocytes) but expressed high levels of the costimulatory 
molecules CD80, CD86 and CD40 (41-, 4- and 7-fold increase, respectively, compared with 
monocytes), and were uniformly positive for the lineage marker CD83 (1.5-fold increase) 
(Figure 8B and Table 7). DC generated without final maturation with LPS, TNF-α and IFN-γ 
expressed lower levels of the costimulatory molecules CD80, CD86, CD40 and CD83 (13.5-, 
2.5-, 1.75- and 1.2-fold increase, respectively, compared with monocytes) compared to fully 
maturated DC. In DC cultures that were used as antigen-presenting cells, a small 
subpopulation (<10% of total cells) of CD14-, CD80-, CD86-, CD83- cells was always present. 
This subset localized in the lymphocyte region (Figure 8A, arrowhead) but contained <5% 
CD3+ cells and was not further characterized. In order to avoid physical cell injury, DCs were 
not irradiated before use in cocultures. 
 
 
Table 7. Characterization of dendritic cells 
 ∆ mean fluorescence 1 fold increase in 
dendritic cells 2  monocytes dendritic cells 
CD14 718±360 18±21 -20 
CD80 0.6±1.2 114±73 41 
CD86 18±9 57±38 3.4 
CD40 0.4±1.3 18±11 7.0 
CD83 1.3±1.1 4±1.9 1.5 
 
1 ∆ mean fluorescence = mean fluorescence “sample” – mean fluorescence “negative control” 
2 fold increase of mean fluorescence  
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Figure 8. Characterization of monocyte-derived DC. (A) Leukocyte gate of CD14-isolated monocytes 
and IFN-α maturated DC. (B) Flow cytometry profiles of the staining of monocytes and IFN-α 
maturated DC for several DC markers. One of 10 experiments with similar outcome is shown. 
 
 
Induction of peptide-specific CTL by monocyte-derived DC 
After optimizing culture conditions, 10 different HLA-A*02 positive healthy male blood donors 
were tested for the presence of circulating, self-reactive CTL precursors using a coculture 
system of peptide-pulsed DC as stimulator and syngeneic CD8+ cells as responder cells. We 
included the immunodominant foreign peptide Flu(58-66) [133, 176] as a positive control in the 
analysis. SMCY(311-319), [161, 162] and DDX5(168-176) [163] as well as the endothelial-selective 
peptides PTRF(56-64) and CD59(106-114) were used as self-antigens for male PBMC donors.  
The autologous CD8+ responder cells were restimulated weekly with peptide-pulsed PBMC 
and the functional cytolytic activity of the peptide-specific CTL population was tested in a 
cytotoxicity assay (Figure 9A-C). For each peptide, 10 independent cultures with cells from 
10 different donors were analyzed. For the viral peptide Flu(58-66), all ten induction cultures 
(100%) displayed potent peptide-specific target cell killing starting after three weeks (Figure 
9A, left panel). Under the culture conditions described, self-reactive CTL specific for 
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SMCY(311-319) emerged in 7 of 10 independent coculture experiments, i.e. 70% of the cultures 
showed specific target cell lysis after 5 weeks (Figure 9A, right panel). For the endothelial-
selective PTRF(56-64) 50% of the cultures showed specific cytotoxic activity after 5 weeks 
ranging from high killing to lower activity (Figure 9C, left panel). For the highly abundant 
DDX5(168-176) and CD59(106-114) only poor killing was observed (Figure 9B+C). Cloning of the 
CTL lines against the highly abundant self-peptides was not successful. These findings 
suggest that a hierarchy of tolerance against self-peptides exists in healthy blood donors. 
 
 
Figure 9. Induction of peptide-specific CTL against foreign and low abundant self-peptides. Cell lines 
were tested weekly from week 3 to 5 for cytotoxic activity in a calcein-release assay. Peptide specific 
lysis was determined using peptide-pulsed and non-pulsed T2 as target cells and CTL as effectors at 
an E:T ratio of 15:1. Shown are ∆ specific lysis of 10 induction cultures for each peptide (A-C). 
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Induction of CTL clones recognizing foreign and self-peptides 
CTL lines for Flu(58-66), SMCY(311-319), and PTRF(56-64), respectively, were cloned with limiting 
dilution at week 5 of the induction culture (Figure 10). All CTL clones were confirmed to 
express a CD8/CD3 double positive phenotype by flow cytometry (Figure 10D). CTL lines 
specific for Flu(58-66), and SMCY(311-319), respectively, showed good peptide-specific killing 
after week 5 of the induction culture and also maintained specificity after cloning with limiting 
dilution (Figure 10A and B). In contrast, although all selected CTL lines showed good peptide 
specificity, specific CTL clones against PTRF(56-64) did never emerge (Figure 10C). Either the 
CTL clones showed nearly no lysis or high unspecific killing. Some of the PTRF(56-64) CTL 
clones displaying high unspecific lysis were tested on the NK cell target K562. Interestingly, 
they all showed high killing of K562 cells consistent with NK-like activity (Figure 10C). 
Overall, 63% of all PTRF(56-64) CTL clones showed a “reprogramming” into a NK-like 
phenotype (Table 8). The NK-like clones maintained CD8 and CD3 positivity (Figure 11) and 
showed many features of NK-CTL as high positivity for CD56 and no expression of CD16 
(Figure 11). 
 
Table 8. Outcome cloning of PTRF(56-64) CTL lines. 
Induction cultures 5 
CTL clones 65 
 CTL clones with no cytotoxic activity 24 
 CTL clones with NK-like activity 41 
 
 
 
 
 
Figure 10. Induction of CTL clones 
recognizing foreign and self-peptides. (A+B) 
Specific and unspecific killing for Flu(58-66) and 
SMCY(311-319)-specific CTL lines and the 
resulting CTL clones. (C) Specific and 
unspecific target cell killing and killing of K562 
cells for PTRF(56-64)-specific CTL lines and the 
resulting 2 phenotypes of CTL clones. E:T 
ratio was 15:1 for all experiments, shown are 
mean and standard deviations of one 
representative experiment in each group. 
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Figure 11. PTRF(56-64)-specific CTL clones are NK-CTL. Analysis of NK-CTL marker of CTL clones 
specific for PTRF(56-64). (A) staining of CD8 cells directly after isolation from PBMC. (B) induction 
cultures specific for PTRF(56-64). (C) PTRF(56-64)-specific CTL clones resulting from cloning with limiting 
dilution. 
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Induction of EC-peptide specific CTL with PFA-fixed T2 cells as target cells 
A possible reason for the failing induction of peptide-specific CTL for PTRF(56-64) and 
CD59(106-114) could be the weak HLA-A*02 binding and the unstable peptide-MHC complex. 
Further, the use of dendritic cells as antigen-presenting cells could provide too many other 
antigens that are more immunodominant than the endothelial peptides. To optimize both 
factors CD8+ T cells were cocultured in an allogeneic system with peptide-loaded T2 cells as 
stimulators to reduce possible other antigenic sites [177]. Further, the peptide-MHC I 
complex was stabilized by mild paraformaldehyde fixation of stimulator cells [178, 179]. To 
verify the stabilization of the pMHC complex, HLA-A*02 binding over time was performed 
with fixed and non-fixed T2 cells. After 4 hrs the decay of the pMHC complex of fixed cells 
was abolished compared to non-fixed cells (Figure 12A). For the resulting CTL clones neither 
the reduction of possible antigenic sites nor the stabilization of the pMHC complex had any 
influence. Like in the autogenic system the PTRF(56-64)- but also the resulting CD59(106-114)-
specific CTL clones showed either no more cytotoxic activity or a change into a NK-like 
phenotype (Figure 12B and C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Induction of endo-
thelial peptide-specific CTL with 
PFA-fixated T2 as target cells. 
(A) Decay of HLA-A*02 binding 
after fixation of the peptide-
MHC I complex with PHA. 
(B+C) ∆ specific lysis of CTL 
clones generated from allo-
specific cultures either against 
PTRF(56-64) (B) or CD59(106-114) 
(C). 
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Improvement of self-reactive CTL induction by inhibition of PD-L1 and caspases 
Programmed death-1 (PD-1)/PD-L1 interactions play an important role in regulating T cell 
activation [98] and members of the caspase family are involved in activation-induced cell 
death [171]. Both pathways participate in peripheral tolerance. Therefore, we tested whether 
inhibiting the two mechanisms in our autologous coculture system would allow the outgrowth 
of DDX5(168-176) and PTRF(56-64)-specific CTL. A monoclonal antibody against PD-L1 and the 
pancaspase inhibitor z-VAD, respectively, were added to the early cocultures (Figure 13) and 
peptide-specific cytotoxic activity was analyzed again in weekly intervals.  
 
 
Figure 13. Improvement of self-reactive CTL induction by PD-L1 and caspase inhibition. Induction 
cultures were treated with an inhibitory anti-PD-L1 antibody and the pancaspase inhibitor z-VAD, 
respectively. Shown is the ∆ specific lysis from week 1 until week 5 compared to untreated cultures for 
SMCY(311-319) (A), DDX5 (148-156) (B) and PTRF(56-64) (C). 
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For SMCY(311-319)-specific cultures inhibited with z-VAD, peptide-specific CTL emerged earlier 
and displayed more potent specific killing that was detectable after 2 weeks already, 
compared to 5 weeks in normal cultures without inhibition. The inhibition by anti PD-L1 
antibody did mildly accelerate the outgrowth of specific CTL that were clearly detectable after 
4 weeks (Figure 13A). For DDX5(168-176), neither anti-PD-L1 nor z-VAD had any influence on 
the outcome of the coculture and outgrowth of peptide-specific CTL failed under all 
circumstances tested (Figure 13B). Similar results were obtained for the other abundantly 
expressed self-peptide PTRF(56-64) (Figure 13C) suggesting that the precursor CD8+ T cell 
number is substantially lower for DDX5(168-176) and PTRF(56-64) than for SMCY(311-319). 
 
 
Characterization of T cell subsets  
The induction of peptide-specific CTL was not only monitored by weekly analysis of the 
cytotoxic activity but also by the examination of the different T cell subsets during the time of 
culture (Figure 14). For Flu(58-66)-specific CTL >85% of the cells were double positive for CD8 
and CD3 after 6 weeks of culture correlating with the highly specific cytotoxic activity. For 
CTL lines against SMCY(311-319) about half of the population was CD8 positive whereas also a 
large part of CD4 positive cells were present. In the cultures induced for PTRF(56-64) we found 
after 6 weeks up to 75% of the population to be CD4 positive with only a small CD8 positive 
population (Figure 14, upper and middle panel). Further characterization of these CD4 
positive cells showed that for PTRF(56-64) cultures, this population was consistent with 
CD4+CD25+ Treg cells (95.7% of CD4+ cells). For SMCY(311-319), 52.6% of the CD4+ cells 
were corresponding to Tregs (Figure 14, lower panel). A smaller number of CD4+CD25+ cells 
also expressed the Treg marker FoxP3 (36.8% in SMCY(311-319) and 14.1% in PTRF(56-64) 
cultures) (Table 9). From these findings we concluded that in cultures against highly 
abundant self-peptides Treg cells may play a role in inhibiting the outgrowth of peptide-
specific CTL. 
 
 
Table 9. CD4+ T cells subsets. 
 Flu(58-66) SMCY(311-319)  PTRF(56-64) 
CD4+FoxP3+ 6.54% 0.71% 0.31% 
CD4+CD25+ 8.28% 40.9% 72% 
CD4+FoxP3+CD25+ 21.9% 36.8% 14.1% 
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Figure 14. T cell subset analysis of induction cultures at week 6. FACS analysis of CD8/CD4 T cell 
subsets of Flu(58-66), SMCY(311-319) and PTRF(56-64)-specific induction cultures after 6 weeks. The gate 
was set for CD3 positive cells and CD8 and CD4 positive populations were analyzed (one 
representative culture). 
 
 
 
3.2.2 Characterization of self-reactive CTL 
 
Functional characterization of self- versus alloreactive anti-SMCY(311-319) CTL 
Since SMCY(311-319) can be used as self- and allopeptide in this experimental system, we 
were able to compare self- and alloreactive CTL clones functionally using the same HLA-
A*02-peptide complex. Self-reactive CTL lines from induction cultures displaying high 
peptide-specific cytotoxic activity for SMCY(311-319) in the presence or absence of the 
pancaspase inhibitor z-VAD were cloned with limiting dilution. The resulting CTL clones 
specific for SMCY(311-319) as an autoantigen were compared to an alloreactive SMCY(311-319) 
clone derived from a patient after sex-mismatched stem cell transplantation [121]. First, the 
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allo- and autoreactive CTL clones were compared in a E:T titration on SMCY(311-319)-loaded 
T2 cells (Figure 15A).  
For the allo- and the autoreactive CTL clone two CTL clones and for the auto-zVAD CTL one 
clone were tested. All five CTL clones showed comparable killing at the same effector:target 
cell ratios and using the same peptide-saturated target cell. We next determined the peptide 
concentration at which half maximal target cell lysis was observed. It was 5x10-11M, 9x10-9M 
and 10-8M for allo, auto, and auto-zVAD CTL (Figure 15B). Interestingly, self-reactive CTL 
clones that emerged in the presence of z-VAD showed a significantly higher plateau killing 
but similar half-maximal peptide concentration compared with CTL clones grown in the 
absence of the pancaspase inhibitor. This suggests that z-VAD during coculture affects cell 
differentiation and potency but not TCR-antigen interactions or affinity of the emerging CTL 
lines. The same pattern was observed in IFN-γ expression (Figure 15C) but as shown 
previously [121], more antigen was required to stimulate cytokine production by CTL than to 
trigger cytolysis. These findings suggest that self-reactive CTL display a lower affinity for the 
same SMCY(311-319) peptide-HLA-A*02 complex than alloreactive CTL.  
This observation was confirmed by a staining with peptide-MHC pentamers (Figure 15D). 10 
days after restimulation, alloreactive CTL clones showed uniform and strong staining for CD8 
and SMCY-HLA-A*02 pentamer (Figure 15D). The self-reactive CTL clone showed less CD8 
expression and virtually no pentamer binding. The high potent, self-reactive CTL clone grown 
in the presence of z-VAD showed weak but detectably more pentamer binding. However, it 
was not enough to influence affinity. 
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Figure 15. Functional characterization of self- and alloreactive anti-SMCY(311-319) CTL. (A) E:T titration 
and (B) peptide titration of an allo- and self-reactive CTL clone specific for SMCY(311-319). (C) 
comparison of IFN-γ expression of allo- and self-reactive SMCY(311-319) CTL after peptide titration. (D) 
Peptide-MHC multimer and CD8 double staining of allo- and self-reactive anti-SMCY(311-319) CTL.  
 
Recognition of endogenously presented peptide by self- versus alloreactive CTL 
We further analyzed the ability of the CTL to recognize endogenously presented SMCY(311-
319) in male target cell lines (Figure 16). The HLA-A*02 positive B cell line JY and EC were 
compared. Target cells were used in killing assays before and after stimulation with IFN-γ 
(100ng/ml) and TNF-α (50ng/ml), two cytokines that upregulate HLA-A*02 expression 
synergistically in EC [125] (Figure 16). To assess maximal CTL-mediated cytolysis, T cells 
were activated by PHA, a lectin which activates the TCR pharmacologically [121]. 
Alloreactive CTL did effectively lyse male B cells and male EC after activation by 
proinflammatory cytokines (Figure 16A and B, left panel). In contrast, autoreactive CTL were 
unable to recognize and kill male B cells or EC even after activation by IFN-γ/TNF-α (Figure 
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16A and B, right panel). Both allo- and autoreactive SMCY(311-319)-specific CTL failed to kill 
female target cells in the absence of PHA (Figure 16A and B).  
 
 
Figure 16. Recognition of endogenously presented SMCY(311-319). The specific lysis of male and female 
target cells is shown. As targets BLC (A) and EC (B) were compared. Target cells were either 
unstimulated or CTL were maximally activated by pharmalogical TCR stimulation with PHA-L. 
 
 
 
3.3 Immunoprotection of EC by the abundant endothelial peptides 
 
3.3.1 Retroviral transduction of EC and BLC with FluM1 
In order to further explore the handling of source proteins for immunodominant viral peptides 
by EC and to improve their antigen-presenting abilities we wanted to establish a retroviral 
transduction system for influenza matrix protein (containing Flu(58-66)). CTL specific for Flu(58-
66) were used as a tool to determine and quantify the amount of Flu(58-66) on the cell surface of 
EC. The flag-tagged retroviral construct of the full length influenza matrix protein M1 was 
cloned into the bicistronic expression vector pQXIN (Figure 17). The transduction of EC was 
successful and stable expression of influenza matrix protein over >40 passages could be 
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obtained. Expression of the transduced construct could be confirmed both at the mRNA and 
at the protein levels (Figure 17A and B). Immunofluorescence staining for Flag showed >90% 
of the EC expressing the construct (Figure 17C). As a control the cells were stained for the 
endothelial cell marker von Willebrand-Factor (vWF).  
 
 
Figure 17. Characterization of influenza matrix protein M1 transduced EC. (A) mRNA expression of Flu 
in 5 transduced EC lines and in uninfected EC as control. (B) Western blot of FluM1 transduced and 
non-transduced EC. (C) Immunofluorescence staining of transduced EC for Flag and vWF showing 
>95% positivity for the transduced construct. 
 
To compare the antigen processing and presentation of EC with another cell line we wanted 
to transduce also a B cell line. Therefore, we chose the male HLA-A*02 positive JY cell line, 
which was also retrovirally transduced for FluM1. The expression of the transduced construct 
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could be confirmed by mRNA expression and immunofluorescence (Figure 18 A and B). In 
contrast to the EC, FluM1 expression in JY cells was not stable and the transduced construct 
was lost after 4 to 5 passages. Therefore, transduced JY cells could not be used as a control 
cell line. 
 
 
Figure 18. Characterization of influenza matrix protein M1 transduced JY cells. (A) mRNA expression 
of Flu in 2 transduced JY lines and in uninfected JY as control. (B) Immunofluorescence staining of 
transduced JY showing over 95% positivity for the transduced construct. 
 
 
3.3.2 Quantification of Flu(58-66) presented by FluM1 transduced EC  
We compared Flu(58-66)-loaded EC and T2 cells in a peptide titration (Figure 19A). Flu(58-66)-
loaded EC are killed less efficiently by a Flu(58-66) specific CTL clone than T2 cells loaded with 
the same peptide. The peptide concentration at which half-maximal target cell lysis was 
observed was 5x10-9M for EC and 2x10-11M for T2 cells. The findings were confirmed 
regarding IFN-γ expression (Figure 19B), but as previously shown, more antigen was 
required to stimulate cytokine production by CTL than to trigger cytolysis. 
We next analyzed the ability of the CTL to recognize endogenously presented Flu(58-66) in 
FluM1 transduced EC (Figure 19C). HLA-A*02 positive and negative EC-Flu were compared. 
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As a negative control, uninfected EC were used. Target cells were used in killing assays 
before and after stimulation with IFN-γ (100ng/ml) and TNF-α (50ng/ml). CTL were used at 
an effector:target cell ratio of 10:1. Flu(58-66) CTL did effectively lyse HLA-A*02 positive FluM1 
transduced EC after activation by proinflammatory cytokines (Figure 19C). In contrast, the 
CTL showed only low or no killing of resting HLA-A*02 positive EC-Flu. (Figure 19C). As 
expected, Flu(58-66)-specific CTL failed to kill HLA-A*02 negative or uninfected target cells. 
When the cytotoxicity assay was performed with higher effector cell numbers the specific 
lysis increased of both EC-Flu with and without stimulation with IFN-γ/TNF-α (Figure 19D). 
 
 
Figure 19. Lysis of FluM1 transduced EC. Comparison of peptide titration of Flu(58-66)-loaded EC and 
T2 cells for specific lysis (A) and IFN-γ expression (B). (C) Specific lysis of FluM1 transduced EC by 
Flu(58-66)-specific CTL. 3 transduced HLA-A*02 positive and 2 negative EC-Flu lines were tested. 
Uninfected EC were used as control. Cells were either resting or stimulated with IFN-γ/TNF-α 
overnight. (D) E:T titration of transduced and uninfected EC with or without cytokine stimulation. 
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As a second approach to quantify the amount of presented Flu(58-66) on EC and T2 cells, 
Flu(58-66)/HLA-A*02-specific F(ab) M1-D12 fragments were used [180]. This recombinant 
humanized F(ab) monomer is specific for Flu(58-66) bound to HLA-A*02 and therefore can be 
considered a TCR-like protein. Compared with CTL-mediated target cell lysis, F(ab) binding 
to the pMHC complex has been shown to be less sensitive to detect antigenic peptides on 
the surface of target cells [121]. Despite this restriction, T2 cells exogenously loaded with 
Flu(58-66) could be detected by the monomeric recombinant F(ab). F(ab) binding was easily 
detectable at 10-4M peptide concentrations and gradually reduced at decreasing peptide 
loading concentrations up to 10-7M. (Figure 20A). However, the sensitivity of the F(ab) 
fragments was too weak to detect endogenously processed Flu(58-66) on FluM1 transduced 
EC (Figure 20B). 
 
 
Figure 20. Quantification of presented Flu(58-66) by F(ab) fragments. The detection of presented Flu(58-
66) by F(ab) fragments was tested on peptide-loaded T2 cells and transduced EC. (A) T2 cells loaded 
with Flu(58-66) in concentrations ranging from 10-4 to 10-8M. (B) FluM1 transduced EC. 
 
 
3.3.3 Effect of cytokines on Flag and Flu(58-66) expression on FluM1 transduced EC  
IFN-γ and TNF-α are two cytokines that upregulate HLA-A*02 expression synergistically in 
EC (Figure 21). Therefore, we were interested to test the effect of both cytokines separately 
and in combination on FluM1 transduced EC. We compared Flag expression by flow 
cytometry on EC that were either unstimulated or stimulated with IFN-γ, TNF-α or both IFN-
γ/TNF-α overnight (Figure 21A and B). As a control served uninfected EC. Stimulation with 
IFN-γ or TNF-α alone increased Flag expression compared to unstimulated EC, whereas 
stimulation with TNF-α led to a higher Flag expression than IFN-γ. However, the combination 
of both cytokines was more potent than stimulation with a single cytokine (Figure 21A and B). 
The same pattern was found when the specific lysis of FluM1-transduced EC was analyzed 
(Figure 21C). EC-Flu stimulated with TNF-α were killed to a higher percentage as targets 
stimulated with IFN-γ or unstimulated. Transduced EC stimulated with the combination of 
both cytokines led to a cytotoxic activity that reached nearly the levels of maximal CTL 
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activation by PHA. Stimulation with proinflammatory cytokines led further to an upregulation 
of several adhesion molecules like VCAM-1, E-Selectin and LFA-3 (Figure 21D). Therefore, 
the presentation of Flu(58-66) by transduced EC can be gradually enhanced after stimulation 
with IFN-γ or TNF-α or both. The increase in Flu(58-66) presentation is due to both upregulation 
of surface molecules and activation of transcription. 
 
 
Figure 21. Effect of cytokines on Flag expression and lysis of transduced EC. Flag expression of 
transduced EC was analyzed by flow cytometry after stimulation with either IFN-γ, TNF-α or both IFN-
γ/TNF-α. As control, uninfected or transduced unstimulated EC were used. (A) FACS profiles and (B) 
∆MFI of Flag expression. (C) Specific lysis of transduced EC with different stimulation. (D) 
Upregulation of adhesion molecules VCAM-1, E-selectin and LFA-3 after IFN-γ/TNF-α stimulation. 
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3.3.4 Proteasome inhibition experiments 
The supply of peptide into the MHC class I pathway is amongst other factors regulated by the 
degradation of proteins by the proteasome. Therefore, we wanted to examine whether 
peptide presentation on EC can be influenced by inhibiting proteasomic degradation and 
determine the time span up to the disappearing of peptide on the cell surface. To inhibit 
proteasomic degradation an irreversible proteasome inhibitor, clasto-lactacystein β-lactone, 
was used. Addition of 1 µM clasto-lactacystein β-lactone to cultured male EC-Flu led to a 
transient down-regulation of both Flu(58-66) and SMCY(311-319) expression (Figure 22A and B). 
The effect started already after 2 hours with maximal inhibition after 4 hours and lasted up to 
24 hours. The inhibition of Flu(58-66) expression reached higher levels than of SMCY(311-319). 
Addition of the proteasome inhibitor led specifically to a decrease of presented peptide and 
had no effect on HLA-A*02 expression as was confirmed by flow cytometry (Figure 22C+D). 
 
 
Figure 22. Effect of proteasome inhibition on peptide and HLA-A*02 expression of EC. Male FluM1 
transduced EC were incubated with clasto-lactacystein β-lactone for different time points (0, 2, 4, 6, 
24h). % inhibiton of Flu(58-66)-specific (A) or SMCY(311-319)-specific lysis (B) was analyzed. (C) 
Upregulation of HLA-A*02 expression upon stimulation with IFN-γ/TNF-α. (D) After addition of the 
proteasome inhibitor HLA-A*02 expression was monitored for different time points (0, 3, 24h). 
 
 
3.3.5 siRNA knockdown of abundant EC peptides 
RNA interference (RNAi) is a powerful tool that can be used to manipulate gene expression 
[181, 182]. One technique of expressing the short double-stranded RNA intermediates 
required for interference in mammalian systems is the introduction of short-interfering (si) 
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RNAs. The proteasome inhibition experiments showed that after inhibiting the supply of 
peptide into the MHC class I presentation pathway the presented peptide on the surface 
dissociated rapidly. Therefore, it was feasible to use as a second approach to modify the 
endothelial peptide repertoire siRNA knockdown of the abundant endothelial peptides. First, 
siRNA for DDX5(168-176), PTRF(56-64) and CD59(106-114) was designed using a online software 
tool provided by Microsynth. Transduced EC were transiently transfected with siRNA using a 
Lipofectamine-based system. Knockdown of all proteins was confirmed by western blot 
(Figure 23). As a negative control, EC transfected with mock siRNA were used. For DDX5(168-
176) a nearly complete knockdown was accomplished after 24 hours and lasted up to 96 
hours. For CD59(106-114), protein levels started to decrease after 48 hours and were 
completely knocked down after 72 hours. PTRF(56-64) knockdown started after 48 hours with a 
maximum at 72 hours. Protein levels increased again after 96 hours. For PTRF(56-64) no 
complete knockdown was accomplished but protein levels could be reduced to <20%. 
Further experiments were performed at 72 hours after siRNA knockdown since at this time 
point all proteins reached minimal expression levels.  
 
 
Figure 23. siRNA knockdown of endothelial-specific proteins. (A) Full protein lysates of EC after 
different time points (24h, 48h, 72h, 96h) after siRNA knockdown were analyzed by western blot. (B) 
Expression of the protein normalized to β-Actin expression. 
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3.3.6 Improved presentation of immunogenic peptides after knockdown of abundant 
EC-specific peptides 
We hypothesized that EC may be protected by the presentation of the abundant endothelial 
peptides from CTL-mediated lysis. Therefore, simultaneous knockdown of PTRF(56-64), 
CD59(106-114) and DDX5(168-176) on uninfected and FluM1 transduced EC was performed and 
differences in Flu(58-66) as well as SMCY(311-319) expression were quantified by Flu(58-66) / 
SMCY(311-319)-specific CTL after 72 hours. As a control, mock siRNA transduced EC were 
used. We found that after complete knockdown the presentation of both endogenously 
presented Flu(58-66) (Figure 24A and B) and SMCY(311-319) (Figure 24C and D) was increased 
(Figure 24), whereas after stimulation of EC with IFN-γ and TNF-α the presentation of both 
peptides decreased. For uninfected EC exogenously loaded with Flu(58-66) the presentation of 
peptide was slightly increased (1.35±0.36-fold) after knockdown whereas for SMCY(311-319) 
nearly no change was seen (1.04±0.18-fold increase). In contrast, endogenous Flu(58-66) was 
expressed at significantly higher levels after knockdown (1.79±0.37-fold, *p=0.0335) (Figure 
24B). For SMCY(311-319) the increase in expression was slightly lower but still significant with 
1.50±0.32-fold higher levels (*p=0.0300) (Figure 24D).  
 
 
Figure 24. Increased presentation of Flu(58-66) and SMCY(311-319) after knockdown of endothelial-specific 
proteins. Uninfected and transduced EC that were unstimulated or stimulated with IFN-γ/TNF-α 
overnight were treated either with siRNA for PTRF(56-64)/CD59(106-114)/DDX5(168-176) or with mock siRNA. 
After 72 hours, specific lysis by Flu(58-66)- (A+B) or SMCY(311-319)-specific (C+D) CTL was analyzed. 
(A+C) shows the % specific lysis for Flu(58-66) and SMCY(311-319), respectively, (B+D) the fold increase.  
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Although RNA interference strategies are reliant on a high degree of specificity, there might 
also potential non-specific effects be induced. It has been shown that transfection of siRNAs 
leads in IFN-mediated activation of the JAK–STAT pathway and global upregulation of IFN-
stimulated genes that may result in a general upregulation of adhesion and MHC class I 
molecules on EC [183]. To exclude the possibility of an increased peptide presentation due 
to upregulation of HLA-A*02 expression by siRNA we analyzed HLA-A*02 and MHC class I 
levels on untreated EC and cells treated with mock or knockdown siRNA. We found that 
there was no difference in HLA-A*02 (Figure 25A) and MHC class I (Figure 25B) expression 
between all conditions, thus, induction of peptide levels due to an increase in HLA-A*02 
expression could be excluded. 
 
 
Figure 25. HLA-A*02 and MHC class I expression levels after siRNA knockdown. Staining for HLA-
A*02 and MHC class I was performed on EC that were untreated or treated either with mock siRNA or 
siRNA for PTRF(56-64)/CD59(106-114)/DDX5(168-176). HLA-A*02 (A) and MHC class I (B) expression were 
analyzed by flow cytometry and the ∆MFI for each condition was calculated. 
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4. Discussion 
 
In this study we have examined endothelial cells as targets for antigen-specific cytotoxic T 
lymphocytes. Several findings supported the accumulating evidence that EC present a 
substantially different repertoire of MHC class I ligands compared with syngeneic leukocyte-
derived cells and that they are protected from CTL-mediated lysis by this mechanism. Here, 
we could show for the first time that EC present a quantitatively different peptide repertoire 
with abundance of PTRF(56-64) and CD59(106-114) that protects EC from CTL-mediated lysis by 
competition with immunogenic peptides for the MHC class I binding site. The abundance of 
the endothelial peptides is mainly caused by the preferential expression of the source 
proteins. Under conditions that were sufficient to generate CTL specific for low abundant self-
peptides induction of CTL against PTRF(56-64) and CD59(106-114) failed. Improvement of culture 
conditions by stabilization of the pMHC I complex or interference with inhibitory pathways 
affected again only the induction of low abundant self-peptides but not EC-specific peptides 
indicating that these peptides are particularly tolerogenic. After modification of the endothelial 
peptide repertoire and knockdown of the abundant peptides, EC became better targets for 
CTL by increased presentation of immunogenic peptides indicating that PTRF(56-64) and 
CD59(106-114) can protect EC by hiding them from CTL-mediated lysis. 
 
 
 
4.1 The functional role and significance of cell-specifically different 
peptide repertoires 
 
Compared to leukocyte-derived cells, EC present a quantitatively different peptide repertoire 
with abundance of two peptides, PTRF(56-64) and CD59(106-114). We found the abundance of 
the endothelial peptides to be mainly caused on the side of processing with a preferential 
expression of the source proteins. The presentation of PTRF(56-64) exclusively on EC was 
explained by the endothelium-specific expression of the source protein. This finding is 
consistent with previous studies that revealed PTRF as a major caveolae-associated protein 
[153] as caveolae are particularly abundant in adipocytes and endothelial cells. In contrast, 
CD59 was found in different cell lines although at a quantitatively different level with a much 
higher expression in EC. The strong expression of the precursor proteins is even able to 
compensate the low binding affinity of the endothelial peptides to HLA-A*02 and their short 
half-life. It has been showed that one important factor for the immunogenicity of a peptide is 
the stability of the pMHC complex [146, 184]. Peptides binding with lower affinity to the MHC 
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class I molecule may form less stable pMHC complexes leading to decreased 
immunogenicity. The presentation of those weak binding peptides may therefore be one of 
the mechanisms to protect EC from CTL mediated lysis. 
There have been several studies about the importance of cell type-specific peptide 
presentation. In the context of allogeneic bone marrow transplantation (BMT) it has been 
shown that CTL directed against minor histocompatibility antigens (mHA) of the patient 
generally cause GVHD, which although a complication in allogeneic BMT, is strongly 
associated with graft-versus-leukemia (GVL) reactivity [185, 186]. The expression of some 
mHAs is restricted to hemopoietic cells, including leukemic cells, others are expressed by 
cells of all tissues [187, 188]. Since mHAs expressed by all host tissues induce GVHD and 
GVL, it is of great importance to identify leukemic restricted Ags because they exert 
antileukemia reactivity without GVHD.  Dolstra et al. identified a CTL clone against a mHA 
with restricted tissue distribution, the B cell leukemia-associated mHA HB-1 [189]. HB-1-
specific CTL exhibited specific cytotoxicity toward leukemic as well as EBV-transformed B 
cells, but not against untransformed B cells or other cell lines. These antigens are of potential 
use in immunotherapy against leukemia because they generate antileukemia reactivity that is 
not associated with GVHD. 
Cell type-specific antigen expression plays also an important role in organ- or cell-specific T 
cell-mediated autoimmune diseases like type 1 diabetes mellitus or multiple sclerosis (MS). 
In type 1 diabetes, the insulin-producing β cells of the pancreas are selectively targeted by 
autoreactive CD8+ T cells and CTL are involved in both initiation of β cell-directed 
autoimmunity and ultimate destruction of β cells preceding manifest disease [2]. In MS, 
autoreactive CD8+ T cells responsive to myelin-derived peptides have been reported that 
have the potential to kill selectively HLA class I-matched oligodendrocytes [3-5].  
Cell type-specific antigens recognized by self-reactive T cells may also be important in the 
course of autoimmune disorders of the blood vessels. Recently, in vitro studies suggested 
that CD8+ T cell-mediated lysis of autologous platelets may contribute to platelet destruction 
in thrombotic thrombocytopenic purpura [190, 191]. In vasculitis, the blood vessel wall is the 
primary site of inflammation. Detailed studies have explored whether the T cells that 
accumulate in the arterial wall during giant cell arteritis are a random representation of the 
peripheral blood repertoire or whether they are selected, as one would expect in the 
presence of a stimulating antigen. It has been found that a small proportion of tissue-
infiltrating T cells isolated from temporal artery biopsy tissues have undergone clonal 
expansion. Notably, T cells with identical TCR sequences were detected in independent and 
nonadjacent segments of the inflamed blood vessel [192]. This observations are compatible 
with antigen-dependent selection of T cells. If it would be possible to generate endothelial 
peptide-specific CTL they should target selectively endothelial cells and lead to autoimmune 
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disorders with blood vessels as targets, e.g. giant cell arteritis. However, our work is the first 
of its kind to prove a endothelial cell-specific peptide repertoire and to discuss cell type-
specific peptide presentation in the context of tolerance. 
 
 
 
4.2 Hierarchy of self-tolerance 
 
We successfully developed a method to reproducibly generate self-reactive CTL against low 
abundant self-peptides. Under the same culture conditions, the induction of CTL against the 
highly abundant endothelial peptides failed. Factors that determine the outcome of a CTL 
response against an antigenic peptide include the strength of costimulatory signals delivered 
by the APC [38, 39], the binding of the antigen to MHC class I of an APC [193, 194] and the 
avidity of the TCR for the pMHC complex [195, 196]. The dendritic cells that were used as 
APC for CTL induction proved to be highly potent stimulators, even for the generation of self-
reactive CTL lines. IL-2 was added exogenously to mimic signal 3 that is usually provided by 
T helper cells. Therefore, lack of costimulatory signals provided by the APC was unlikely to 
limit the induction of CTL. With the adjustment of the peptide concentrations the low HLA-
A*02 binding was compensated and could be excluded as a reason for the failing outgrowth. 
The failure of induction of self-reactive CTL against abundant endothelium-specific peptides 
indicates a complete absence of circulating precursor CTL that recognize their cognate 
pMHC complex with enough avidity. According to this, we found that preCTL for the 
endothelial peptides in the blood of healthy controls as well as of patients with 
atherosclerosis could not be identified (data not shown). These findings imply that there are 
different levels of immunological tolerance against low abundant and high abundant self-
peptides. Thymic negative selection most effectively deletes those T cell precursors that 
express TCR having high avidity for self-pMHC complexes expressed on medullary DC and 
mTEC. Thus, peripheral immune tolerance mechanisms are most important for controlling 
mature T cells that bear a TCR of relatively low avidity for self pMHC and that escape to the 
periphery [197]. As the generation of CTL specific for the self-peptide SMCY(311-319) is 
feasible, thymic negative selection of naïve CTL seems not to be the reason for the 
tolerance. Thus, this may rather occur on the side of peripheral tolerance mechanisms as 
costimulatory molecules (like the PD-1/PD-L1 pathway), regulatory T cells, anergy induction 
by caspases, or exhaustion of T cells after continous contact with abundant peptides [96]. 
Negative or inhibitory costimulatory molecules like PD-1 are modulators of autoimmunity that 
regulate T cell activation and play a role in peripheral tolerance. PD-1 and its ligands regulate 
both the induction and maintenance of peripheral CD8+ T cell tolerance [92] and are involved 
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in the restoring of exhausted T cells [94]. Members of the caspase family are involved in 
activation-induced cell death [171] which is known to have a tolerogenic effect by leading to a 
self-limiting CTL response and deletion of autoreactive T cells [198]. However, the inhibition 
of costimulatory pathways like the PD-1/PD-L1 pathway or of caspases during the induction 
of CTL led only to an earlier outgrowth of self-reactive CTL against low abundant self-
peptides but had no effect on CTL against abundant peptides. Therefore, these mechanisms 
seem not to be involved in the tolerance against the endothelial peptides. 
Tolerance induction against self-peptides depends further on the quantitative level [196], the 
localization and the persistence of antigen presentation [199]. CTL against antigenic peptides 
with persistent and high presentation on professional APC in the lymphohematopoietic 
system will eventually be eliminated by exhaustive induction or clonal deletion [199] 
contributing to the self-limitation of tissue-specific autoimmunity. The exposed position of EC 
and their intimate contact with lymphocytes in the microcirculation could increase tolerance 
against endothelium-specific peptides, either by inducing long-lasting anergy, peripheral 
deletion of PTRF(56-64) and CD59(106-114) specific CTL or exhaustion as it is seen for chronic 
infections [95-98]. SMCY(311-319)-specific CTL on the other hand which survived central 
tolerance are not completely tolerized in the periphery due to the relatively low amount of 
antigen presented [121]. 
Preliminary data in our lab showed that it might be possible to generate peptide-specific CTL 
for the highly abundant leukocyte-derived antigen PP1A(11-19). If this proves to be the case 
then not only a hierarchy in tolerance may be involved in the failure of anti-endothelial 
peptide-specific CTL induction but also cell type-specific antigen expression. On argument 
against this theory may be the impossibility to induce CTL specific for the highly abundant 
DDX5(168-176). However, DDX5(168-176) is no leukocyte-derived peptide but abundantly 
expressed on EC as well. Therefore, peptides expressed only on cells that are able to 
provide enough costimulation may not lead to activation-induced cell death whereas preCTL 
specific for peptides presented also on endothelial cells that provide poor costimulation may 
be eliminated peripherally. 
In a few cultures CTL lines specific for PTRF(56-64) could be induced. Interestingly, those CTL 
lines showed a ‘reprogramming’ into cells with NK-like activity after clonal expansion. NK-
CTL have previously described in literature as CD3+CD4+ or CD8+CD56+CD16- cells that 
possess one single TCRVβ. They are able to lyse certain NK targets and express HLA class 
I-specific NK receptors (NKR) [200]. The NKR on CD8+ T cells are in most situations 
dependent on TCR signaling for their function and work as utensils modulating T cell 
responses [201, 202]. It has been shown that these reprogrammed CTL have always 
undergone significant oligoclonal or monoclonal T cell expansions [200]. The PTRF(56-64)-
specific CTL clones expressed several features of NK-CTL like a CD8+CD56+CD16- 
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phenotype and lysis of the NK target K562 whereas the CTL lines specific for PTRF(56-64) 
before cloning did not express a NK-like phenotype. Therefore, the reprogramming is likely to 
occur during the clonal expansion phase of the CTL culture. The transformation of CTL into 
more “innate-like” cells with NK cell properties has been found previously under different 
conditions. Bjorkstrom et al. showed elevated number of CTL with NK-like properties in 
chronic HCV infection, which showed evidence for clonal expansion as well as TCR-
independent effector functions [203]. CD8+ cells expressing NK associated receptors were 
found to be increased in melanoma patients and to display an effector phenotype [204]. The 
reprogramming of CTL into NK-like cells in celiac disease led to a stepwise transformation of 
CTL to more ‘innate-like’ cells with the properties of NK cells and upregulation of multiple 
activating NKR on oligoclonally expanded IFN-γ-producing effector T cells [205]. From these 
studies there is accumulating evidence that NK receptors can modulate antigen-driven T cell 
responses. The interaction between inhibitory NKR expressed on NK and NK-like cells and 
MHC molecules expressed on normal cells leads to the inhibition of NK-cell function. By 
contrast, failure to express MHC molecules may render tumor or virus-infected cells 
susceptible to NK-mediated lysis [206, 207]. Understanding of the mechanism regulating the 
surface expression of inhibitory NKR may be particularly important for the implications in the 
negative regulation of T cell responses. The expression of inhibitory NKR may be detrimental 
to the host in case of CTL responses to cytopathic viruses or tumor cells. For example, in the 
case of chronic viral infections, this inhibitory phenomenon may lead to a less efficient control 
of virus replication. On the other hand, the expression of inhibitory NKR by autoreactive T 
lymphocytes could be potentially useful in certain autoimmune diseases. Moreover, a similar 
favorable situation can be envisaged if NKR expression occurs in vivo in alloreactive CTL 
during transplantation. It has been suggested that the stepwise transformation of CTL into 
more ‘innate-like’ cells with NK cell properties is one underlying mechanism for 
immunopathology in chronic inflammatory diseases [205] and may result from prolonged CTL 
stimulation due to chronic infection. However, the underlying mechanism and significance of 
the reprogramming transformation of PTRF(56-64)-specific CTL has yet to be examined. 
Regulatory T cells (Treg) have been shown to be crucial for the maintenance of self-
tolerance and to control CD8+ T cell effector functions. Recently, it has been reported that 
self-reactive Treg are able to control CTL priming in an antigen-specific manner at the level 
of T cell expansion and prevent the induction of autoimmune responses through selective 
blockade of autoreactive T cell proliferation [208]. We found that in CTL cultures induced 
against self-peptides also a large population of CD4 cells emerged and increased during 
culture time. Further characterization showed that the population was CD4+CD25+ 
corresponding to Tregs. In cultures against low abundant self-peptides about a quarter of the 
cells accounted for the Treg population. In contrast, in cultures against the highly abundant 
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endothelial peptides, up to 75% of the cells were CD4+CD25+. It is imaginable that this 
population is able to influence and even control the outgrowth of self-reactive CD8+ T cells in 
an antigen-specific manner. Further, early elimination of this population might enable T cell 
expansion and allow endothelial peptide-specific CTL to emerge. 
From all these findings, we conclude that there exists a hierarchy of tolerance dependent on 
the abundance of the antigen. T lymphocytes specific for low abundant peptides can escape 
central tolerance mechanisms and are ignored in the periphery whereas highly abundant 
peptides lead to the efficient deletion of precursor CTL probably by using mechanisms of 
peripheral tolerance like clonal exhaustion of T cells, induction of inhibitory antigen-specific 
Tregs or the reprogramming into NK-CTL  
 
 
 
4.3 Stealth effect of endothelial peptides 
 
In this study, we provide evidence for the first time that the predominant presentation of 
endothelium-specific antigens can protect EC from CTL-mediated lysis by competing with 
immunogenic peptides for the binding site on MHC class I molecules. Since CD8+ T cells with 
high avidity for self-peptides are deleted by negative selection in the thymus [209], self-
reactive CTL usually have low avidity for self-peptides and require a higher amount of pMHC 
complexes per target cell for efficient recognition and killing [196]. By the predominant 
presentation of PTRF(56-64) and CD59(106-114) against which no circulating CTL are detectable, 
these peptides could outnumber immunodominant peptides and thereby hide EC from an 
immune attack. With the transduction of the immunodominant FluM1 gene into male EC we 
got a system that allows not only to analyze two endogenously processed antigens at the 
same time but where antigen expression can also be induced and modulated by 
proinflammatory cytokines. Inhibition of the proteasome in this system led to a decrease in 
both Flu(58-66) and SMCY(311-319) expression with unchanged levels of HLA-A*02. These 
findings confirmed that first, the presentation of the peptides can be influenced by inhibition 
of proteasomic degradation, second the pMHC complex dissociates at a reasonable time 
span and third, the proteasome inhibitor did not influence HLA-A*02 levels but decreases the 
amount of peptide on the surface by specifically diminishing the supply of peptide into the 
MHC class I pathway. Knockdown of the abundant endothelial peptides PTRF(56-64), CD59(106-
114) and DDX5(168-176) by RNA interference led to an increased presentation of other 
endogenously processed peptides proving that without the abundant endothelial peptides EC 
become better targets for both Flu(58-66) and SMCY(311-319)-specific CTL. 
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In previous studies, several observations have been made that support our findings. Murine 
lung EC have been shown to negatively regulate CD8+ T cell function [106]. Bolinger et al. 
showed in a mouse model that vascular EC expressing minor histocompatibility antigens are 
immunologically ignored by specific CD8+ T cells unless CTL are primed by DC cross-
presenting the endothelial antigens [210]. Further, autoreactive CTL against two 
endothelium-specific peptides have been identified [211, 212]. However, those peptides are 
derived from KDR (Kinase insert domain-containing receptor) and CD105 (Endoglin) but are 
expressed on angiogenic, proliferating EC only. Therefore, the presentation of these 
immunogenic peptides is temporally and spatially restricted. This is a sharp contrast to the 
constitutive and ubiquitous expression of CD59(106-114) and PTRF(56-64) on EC and may be a 
possible condition to break the balance between EC-induced active peripheral tolerance and 
ignorance by disguise. However, our work is the first of its kind providing evidence for a 
endothelium-specific repertoire that protects EC from CTL-mediated lysis. 
 
 
 
4.4 Limitations, importance and summary of the study 
 
One of the limitations of this study may be that the experiments were performed with cells 
from human donors only, therefore our data result from cell culture models but cannot be 
compared with a compatible in vivo model. On the other hand, our model provides 
advantages as the antigen expression can be modulated by cytokines, proteasome inhibition 
or RNA interference. The analysis of the human CTL repertoire is usually limited to the 
peripheral blood. The fact that we could not generate CTL against PTRF(56-64) and CD59(106-
114) from circulating peripheral blood cells does not rule out that such autoreactive CTL might 
be found in other tissues. However, CTL lines grown out from arterial tissue samples from 
patients with atherosclerosis were tested for specific lysis of PTRF(56-64)/CD59(106-114)-loaded 
cells but also failed to recognize specifically the endothelial peptides (data not shown). 
Furthermore, it remains open whether PTRF(56-64) and CD59(106-114) could be recognized 
during auto- or alloimmune vascular diseases as the PBMC used in this study were taken 
from healthy donors. However, precursor CTL for the endothelial peptides could not be 
identified in both healthy donors and patients with atherosclerosis (data not shown). We tried 
to improve the culture conditions by blockade of inhibiting costimulatory pathways that are 
known to play a role in tolerance but this affected only the induction of CTL against low 
abundant self-peptides. However, the blockade of the PD-1/PD-L1 pathway may not be 
enough to break the tolerance as it has been shown that PD-1 and CTLA-4 have distinct, yet 
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possible synergistic roles [213]. Therefore, blockade of both pathways may be inevitable to 
affect also the outgrowth of endothelial-peptide specific CTL.  
The importance of self-reactive CD8+ effector T cells in autoimmune diseases has become 
more and more clearer. Yet, there is still lack of measures to detect self-reactive T cells, 
especially in the human setting. First, the relevant (disease-associated) self-reactive T cells 
act in the tissue lesion, and only circulate at very low precursor frequencies in the peripheral 
blood. Second, the autoantigens are mostly unknown as the identification of autoantigens is 
extremely difficult. Therefore, methods that enable and improve the induction and 
examination of self-reactive CTL may have implications for the diagnostic and therapy of 
autoimmune diseases.  
The integrity of the endothelium is crucial for the maintenance of organ homeostasis and 
endothelial dysfunction has devastating effects on the organism. It can be caused by 
inflammation and immune-mediated injury and is the first step in the formation of 
atherosclerosis. Here, we show that EC have an immune privilege due to presentation of a 
quantitatively different peptide repertoire. Our findings have several implications for the 
diagnostic and therapy of immune-mediated endothelial diseases. First, the mechanism that 
endothelial cell-specific surface expression of MHC class I-bound peptides leads to efficient 
tolerance could be explored in other contexts of cell-specific antigen expression such as 
desensitizing individuals who suffer from CTL driven, organ-specific autoimmune disease 
(e.g. diabetes mellitus). This would also point to novel targets for organ-specific 
immunosuppression. Our findings have as well further implications for the pathogenesis of 
alloimmune diseases such as GVHD. They may explain why mature, fully differentiated 
effector CTL that were activated by dendritic cells in secondary lymphoid organs tend to 
ignore vascular EC on their way to the epithelial compartment of the affected organ, e.g. 
skin, gut, or liver [117]. Unless the CTL manage to express a sufficiently high amount of the 
immunogenic antigen against which specific CTL are directed, CTL are not triggered to 
release cytolytic granules and therefore do not kill these cells. 
In this study, we showed for the first time that EC are protected from CTL-mediated lysis by 
the presentation of an endothelial cell-specific peptide repertoire. The abundance of the 
endothelial peptides is mainly caused by the preferential expression of the source proteins. 
The mechanism of protection consists from different layers of tolerance induction. First, the 
endothelial peptides compete with immunogenic peptides for the MHC class I binding site. 
Second, the endothelial peptides have distinct properties like weak binding to the MHC I 
molecule and unstable pMHC complexes that may participate in the protection by reducing 
the immunogenicity of the peptides. Third, the selective and abundant presentation of 
PTRF(56-64) and CD59(106-114) on EC leads to the complete elimination of self-reactive CTL 
specific for these peptides. Fourth, even the improvement of culture conditions like the 
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blockade of inhibitory pathways did not enable the induction of CTL against EC-specific 
peptides. And fifth, after cloning of PTRF(56-64)-specific CTL lines, cells with NK-CTL 
phenotype did emerge that might be able to modulate antigen-driven T cell responses. Thus, 
by these mechanisms, EC avoid being targeted by CTL despite their continuous intimate 
contact and become an immune privileged site supporting their crucial role in organ 
homeostasis. 
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